Finex logo
Finex Intelligence

Market Signal Briefing

Wire-ready dashboard awaiting your first source connection.

Last news saved at Mar 30, 13:54 1mo ago Cron last ran Mar 30, 13:54 1mo ago Awaiting first source
Switch language
91,488 Stories ingested Auto-fetched market intel nonstop.
0 Distinct tickers Add sources to start tracking symbols
Trending sources Waiting for fresh intel
Hot tickers Surfacing from current coverage
Details Saved Published Title Source Tickers
2025-11-11 16:36 5mo ago
2025-11-11 11:26 5mo ago
Scandinavian Tobacco Group A/S Reports Third Quarter 2025 Results and Narrows Expectation Ranges for Full-Year. stocknewsapi
SNDVF
Company Announcement
No. 16/2025

Copenhagen, 11 November 2025

Interim report, 1 January – 30 September 2025

Scandinavian Tobacco Group A/S Reports Third Quarter 2025 Results and Narrows Expectation Ranges for Full-Year.
 

For the third quarter 2025, reported net sales were DKK 2.4 billion with organic net sales in line with last year. EBITDA before special items was DKK 519 million with an EBITDA margin of 22.0% compared with 23.4% last year. Free cash flow before acquisitions was DKK 173 million and the adjusted EPS were DKK 3.4. The results support the full-year expectations.

The reported net sales were negatively impacted by exchange rate developments. Organic growth was positive in the product categories Handmade Cigars and Next Generation Products, whereas Machine-Rolled Cigars & Smoking Tobacco delivered negative organic growth. The underlying business trends remain largely unchanged, though the decline rate in handmade cigars show early signs of stabilising.

The EBITDA margin before special items continued to recover in the third quarter compared with the first two quarters of the year leaving the margin for the first nine months of the year at 19.9% (22.0%). The decline in the margin compared with last year is driven by a combination of product and market mix and investments in stabilising our market shares in machine-rolled cigars in key European markets. Free cash flow before acquisitions for the first nine months improved to DKK 448 million primarily driven by changes in working capital and lower investments offsetting the decrease in EBITDA.

Third Quarter 2025

Reported net sales decreased by 3.0% to DKK 2.4 billion (DKK 2.4 billion)Organic net sales growth was slightly up by 0.3% (-0.1%)EBITDA margin before special items was 22.0% (23.4%)Adjusted EPS were DKK 3.4 (DKK 4.1)Free cash flow before acquisitions was DKK 173 million (DKK 275 million). Return on Invested Capital (ROIC) was 8.3% (9.8%). First nine months 2025

Reported net sales decreased by 0.8% to DKK 6.7 billion (DKK 6.7 billion)Organic net sales growth was negative by 4.0% (0.9%)EBITDA margin before special items was 19.9% (22.0%)Adjusted EPS were DKK 8.2 (DKK 9.9)Free cash flow before acquisitions was DKK 448 million (DKK 327 million) CEO Niels Frederiksen commented: “In the third quarter we saw early signs of stable sales but continued margin compression, driven by market and product mix as well as a more intense promotion environment. I am pleased that we have grown both the handmade and the nicotine pouch business in the quarter, but our market share performance in machine-rolled cigars has been negatively impacted by instability created by the roll out of our global SAP solution. On 20 November we will launch our next 5-year strategy and I look forward to sharing details on the Group’s ambitions and how we intend to create meaningful value for our stakeholders for the years ahead”.   

Financial expectations for full year 2025

The financial expectations for full year 2025 have been narrowed to reflect increased full-year visibility with less than two months to go and to reflect the USD development. The biggest uncertainties to the expectations are US consumer sentiment, down trading and retailer decisions on inventory levels across our product categories as well as the development of the USD, which can impact reported net sales.

Guidance and assumptions are based on no impact from potential new acquisitions and at exchange rates as of the reporting date.  A 10% change in the USD/DKK exchange rate would impact group net sales by approximately 5 percentage points with EBITDA margins being only marginally impacted.

For further information, please contact:
Torben Sand, Director of IR & Communication, phone +45 5084 7222, [email protected].
Eliza Dabbagh, IR & Communications, phone +45 5080 7619, [email protected].

A conference call will be held on 12 November 2025 at 10.00 CEST. Dial-in information and an accompanying presentation will be available at investor.st-group.com/investor around 09:00 CEST.

Launch of Five-Year Strategy and Capital Markets Day - 20 November 2025
The five-year strategy Rolling Towards 2025 is coming to an end and as communicated, Scandinavian Tobacco Group will launch its updated five-year strategy on 20 November 2025, CET 14.00-16.30. The Group management will host a livestreamed virtual Capital Market Event. Link for more detail and registration:

https://www.st-group.com/investor/capital-markets-day-2025/

Interim report Q3 2025
2025-11-11 16:36 5mo ago
2025-11-11 11:30 5mo ago
iPower Regains Compliance with Nasdaq Minimum Bid Price Requirement stocknewsapi
IPW
November 11, 2025 11:30 ET

 | Source:

iPower, Inc.

RANCHO CUCAMONGA, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- iPower Inc. (Nasdaq: IPW) (“iPower” or the “Company”) today announced that it has received written notice from The Nasdaq Stock Market LLC (“Nasdaq”) confirming that the Company has regained compliance with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) and that the matter is now closed. Nasdaq’s notice stated that for the ten consecutive business days from October 27, 2025 to November 7, 2025, the closing bid price of the Company’s common stock was at or above $1.00 per share.

As previously disclosed, on January 2, 2025, Nasdaq notified the Company that its common stock had failed to maintain a minimum bid price of $1.00 over the prior 30 consecutive business days, as required by the Nasdaq Listing Rules. With Nasdaq’s latest notification, iPower is once again in compliance with Listing Rule 5550(a)(2).

About iPower Inc. 

iPower Inc. (Nasdaq: IPW) is a technology- and data-driven online retailer and a provider of value-added e-commerce services for third-party products and brands. iPower operates a nationwide fulfillment network and is expanding infrastructure across software, logistics, and manufacturing, with an aim to also pursue initiatives in digital assets and blockchain integration. For more information, please visit www.meetipower.com.

Forward-Looking Statements 

All statements other than statements of historical fact in this press release are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that iPower believes may affect its financial condition, results of operations, business strategy, and financial needs. Investors can identify these forward-looking statements by words or phrases such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "potential," "continue," "is/are likely to" or other similar expressions. iPower undertakes no obligation to update forward-looking statements to reflect subsequent events or circumstances, or changes in its expectations, except as may be required by law. Although iPower believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and iPower cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results and performance in iPower's Annual Report on Form 10-K and in its other SEC filings, including its Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.

Media & Investor Contact

[email protected]
2025-11-11 16:36 5mo ago
2025-11-11 11:30 5mo ago
ONNIT Migrates to Ordergroove and Shopify to Accelerate Growth and Elevate the Wellness Subscriber Journey stocknewsapi
SHOP
NEW YORK, Nov. 11, 2025 (GLOBE NEWSWIRE) -- ONNIT, the Unilever-owned health and wellness brand best known for its flagship nootropic Alpha Brain®, has migrated its five-figure subscriber base to Ordergroove and Shopify with a 99.6% success rate and no downtime.

ONNIT now operates on a best-in-class tech stack that gives the brand the scale and flexibility to go beyond “subscribe and save” and unlock new avenues for profitable recurring revenue. The integration of Ordergroove and Shopify creates a unified foundation that combines world-class commerce with enterprise-grade subscriptions, improving performance, simplifying operations, and delivering more engaging customer experiences.

Building on its new tech foundation, ONNIT rolled out a refreshed brand experience with conversion-focused UX and made subscriptions the centerpiece of its growth strategy. It also frees up valuable resources that used to be focused on maintaining their homegrown subscription system, lowering total cost of ownership and increasing speed to market.

ONNIT joins an impressive roster of Unilever brands powered by Ordergroove, including OLLY, Tatcha, Kate Somerville, Living Proof, and Blueair.

Prior to this shift, ONNIT’s homegrown system supported its early subscription success, but the brand needed a more scalable solution to deliver the loyalty-driven experiences it envisioned. Today, Ordergroove and Shopify enable ONNIT to focus on data-driven strategies such as prepaid models and A/B-tested promotions that boost lifetime value, while freeing internal resources to deliver more personalized and customizable subscriber experiences.

“Our customers are at the heart of everything we do, and moving to Ordergroove and Shopify gives us the ability to uplevel their experience and ensure they always have the ONNIT products they rely on, exactly when they need them,” said Danae Young-Lagoeiro, Director of Retention. “Our new tech stack allows us to offer more flexibility, introduce new innovations, and build the kind of long-term relationships that fuel loyalty and growth.”

Ordergroove gives ONNIT the tools to grow faster, reduce churn, and scale efficiently, including:

Prepaid subscriptions: Drive predictable revenue and long-term commitment, while giving subscribers the flexibility to choose how they payFlexible promotions and A/B testing: Optimize enrollment and retention with data-driven insights that translate into profitable and sustainable growthSeamless Shopify integration: Combine the global leader in commerce with enterprise-grade subscriptions to simplify operations, accelerate launches, and deliver best-in-class subscriber experiencesScalable architecture: Confidently support subscriber growth and new product launches without straining internal resources, ensuring stability as the business expands "ONNIT's migration showcases exactly what happens when forward-thinking brands combine Shopify's commerce infrastructure with best-in-class subscription technology—they unlock growth that was previously impossible with legacy systems,” said Josh Rice, VP of Sales at Shopify. “This partnership exemplifies how enterprise brands are choosing integrated, scalable solutions over custom builds to drive profitable recurring revenue and deliver the personalized experiences today's subscribers demand."

“ONNIT is a proven leader in health and wellness, and innovating their subscription strategy underscores their commitment to putting customer experience at the center of growth,” said Greg Alvo, CEO and Founder of Ordergroove. “This migration signals how leaders in every category are elevating subscriptions from a convenience feature to a strategic growth driver.”

ONNIT’s migration highlights a broader shift in commerce, where enterprise brands are transitioning away from custom-built systems and toward integrated, industry-leading platforms that can scale efficiently and drive profitable growth.

ABOUT ORDERGROOVE
Ordergroove enables subscription and membership experiences for the world’s largest and most innovative brands and retailers, including L’Oréal, Dollar Shave Club, La Colombe Coffee, Bonafide Health, PetSmart, and The Honest Company. As a market leader in subscription and membership technology, the company’s proprietary Relationship Commerce platform is shifting consumer interactions from one-and-done transactions to frictionless and highly profitable recurring relationships. Ordergroove technology uses artificial intelligence, analytics, and unmatched consumer expertise to empower top brands to transform their commerce experiences while making their consumers’ lives easier. To learn more, visit www.ordergroove.com.

ABOUT ONNIT
ONNIT is a cutting-edge supplement brand dedicated to Total Human Optimization: enhancing physical, mental, and recovery performance through science-backed innovation. Founded in Austin, Texas, ONNIT empowers people to perform at their best with products like Alpha BRAIN®, a leading nootropic for focus and cognitive support, and Total Human®, a complete daily system for simplified, effective wellness. Greatness isn’t given; it’s forged. At ONNIT, every product is built to help you unlock your full potential. Begin your Total Human Optimization journey at ONNIT.com.

ABOUT SHOPIFY
Shopify is a leading global commerce company that provides essential internet infrastructure for commerce, offering trusted tools to start, scale, market, and run a retail business of any size. Shopify makes commerce better for everyone with a platform and services that are engineered for speed, customization, reliability, and security, while delivering a better shopping experience for consumers online, in store, and everywhere in between. Shopify powers millions of businesses in more than 175 countries and is trusted by brands such as Aldo, BarkBox, BevMo, Carrier, David’s Bridal, JB Hi-Fi, Mejuri, Meta, SKIMS, Supreme, and many more.
2025-11-11 16:36 5mo ago
2025-11-11 11:31 5mo ago
STG A/S - Interim consolidated financial statements of Scandinavian Tobacco Group A/S stocknewsapi
SNDVF
Company Announcement – Euronext Dublin
No. 05/2025

Copenhagen, 11 November 2025

STG A/S - Interim consolidated financial statements of Scandinavian Tobacco Group A/S

On 11 November 2025, Scandinavian Tobacco Group A/S published its consolidated interim report for 1 January – 30 September 2025.

The company announcement of Scandinavian Tobacco Group A/S relating to the published interim report is available at: https://www.st-group.com/investor/news/.

For further information, please contact:
Torben Sand, Director of IR & Communication, phone +45 5084 7222 or [email protected]

STG Group Ireland - Company Announcement no 5 2025
2025-11-11 16:36 5mo ago
2025-11-11 11:31 5mo ago
BigBear.ai Holdings, Inc. (BBAI) Q3 2025 Earnings Call Prepared Remarks Transcript stocknewsapi
BBAI
BigBear.ai Holdings, Inc. (BBAI) Q3 2025 Earnings Call November 10, 2025 4:30 PM EST

Company Participants

Sean Ricker - CFO & Principal Accounting Officer
Kevin McAleenan - CEO & Director

Presentation

Operator

Greetings, and welcome to BigBear.ai Holdings, Inc. Third Quarter 2025 Earnings Call and Webcast. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Chief Financial Officer, Sean Ricker.

Thank you, sir. Please go ahead.

Sean Ricker
CFO & Principal Accounting Officer

Good afternoon and thank you all for joining us today for our third quarter 2025 earnings call. I'm Sean Ricker, CFO of BigBear.ai and I'm joined today by our CEO, Kevin McAleenan. Statements made in today's call that are not historical facts are considered forward-looking statements and are made pursuant to the safe harbor provisions of the federal securities laws. Actual results may differ materially from those projected in the forward-looking statements. Please see today's press release and our SEC filings for a description of some of the factors that may cause actual results to differ materially from those in the forward-looking statements.

We have posted charts on our website today that we plan to address during the call to supplement our comments. These charts also include information regarding non-GAAP measures that may be used in today's call. Please access our website at www.bigbear.ai and click on the Investor Relations link to view and follow the charts.

With that, I'd like to turn the call over to Kevin.

Kevin McAleenan
CEO & Director

Good afternoon. It's good to be back speaking with our shareholders and analysts about our progress today. Three months ago, I told you BigBear was going on offense, taking advantage of our positioning in the market and our increased capital to grow organically and to strengthen our position

Recommended For You
2025-11-11 16:36 5mo ago
2025-11-11 11:31 5mo ago
Solesence, Inc. (SLSN) Q3 2025 Earnings Call Transcript stocknewsapi
SLSN
Solesence, Inc. (SLSN) Q3 2025 Earnings Call November 11, 2025 8:30 AM EST

Company Participants

Kevin Cureton - President & CEO
Jess Jankowski
Laura Riffner - Chief Financial Officer

Conference Call Participants

Wayne Rowan
Ron Richards

Presentation

Operator

Good day, and thank you for standing by. Welcome to the Solesence Third Quarter 2025 Conference Call. [Operator Instructions] Please note that this conference is being recorded.

During this call, management will make statements that include forward-looking statements within the meaning of the federal securities laws, which are pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995.

This conference call may contain statements to reflect the company's current beliefs and a number of important factors could cause actual results for future periods to differ materially from those stated on this call. These important factors include, without limitation, a decision of the customer to cancel purchase order or supplies, agreement, demand for an acceptance of the company's personal care ingredients, advanced materials and formulated products, changes in development and distribution relationships, the impact of competitive products and technology, possible disruption in commercial activities occasioned by public health issues, terrorist activity and armed conflict and other risks indicated in the company's filings with the Securities and Exchange Commission.

Except as required by federal securities laws, the company undertakes no obligation to update or revise these forward-looking statements to reflect new events, uncertainties and other contingencies. I now hand the conference over to Kevin Cureton, President and Chief Executive Officer. Please go ahead, sir.

Kevin Cureton
President & CEO

Thank you, operator. And thank you to all of our investors, teammates and friends joining us today. We have a lot to cover, so we appreciate your time, patience and attention. Today is a meaningful moment in the history of Solesence. This is my first opportunity to speak with

Recommended For You
2025-11-11 16:36 5mo ago
2025-11-11 11:32 5mo ago
Cavco Industries: Acquisition And Buybacks Build A Compelling Case stocknewsapi
CVCO
SummaryCavco Industries delivered strong Q2 results with 9.6% YoY revenue growth, driven by factory-built housing and strategic production adjustments.CVCO's acquisition of American Homestar expands its presence in high-growth southern regions, boosting market share to 15% and retail locations to 100.Despite a premium 22x forward P/E, CVCO's robust EPS outlook, debt-free balance sheet, and active buyback program support further upside potential.Compared to peers, CVCO stands out with superior growth and profitability, benefiting from macroeconomic tailwinds and a diversified geographic footprint. timnewman/E+ via Getty Images

Introduction: A One-Stop Shop for Affordable Homes - Cavco’s Growth Story Strengthens Cavco Industries (CVCO) is the third-largest factory-built homes designer, manufacturer, and seller. Cavco is heavily focused on the South and Farwest, where the demand is high

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You
2025-11-11 16:36 5mo ago
2025-11-11 11:32 5mo ago
These Dow Stocks Have Crushed the VOO and VTI in 2025—Here's Where They're Headed Next stocknewsapi
CAT GS
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

© Scott Olson / Getty Images

The Dow Jones Industrial Average offers too small a sample size for many to be an effective gauge of how well the stock market is doing on any given day. But, of course, we have the S&P 500 for that, which is more widely followed and invested in by investors. Still, having only 30 stocks in a basket does make the Dow an interesting and reasonably well-diversified portfolio that might act as a model for new investors looking to get started in the stock-picking game.

Of course, the Dow Jones basket can be fun to keep tabs on as a beginner. And, of course, the index has a very rich history on Wall Street alongside a price that’s continued to swell, serving as an example of the wonders of compounding over extremely long periods of time. In any case, if you’re a fan of blue chips and are interested in when the legendary index adds a new holding or gives one the boot, you might be compelled to see what’s winning or losing in any given year.

Though the year isn’t over yet, this piece will explore a few Dow stocks that have had their way with the Vanguard S&P 500 ETF (NYSEARCA:VOO) and Vanguard Total Stock Market Index (NYSEARCA:VTI), which are both up close to 15%, so far this year. But does their recent hot streak warrant chasing them into the new year? Let’s find out.

Caterpillar
Caterpillar (NYSE:CAT) is a heavy-duty construction machinery company that I found to be one of the most surprising market beaters for 2025. Shares of Caterpillar are up over 56% year to date, and despite recent turbulence, the rally off Liberation Day lows still seems intact. Wall Street analysts have high hopes for the $263 billion industrial blue chip going into 2026, especially after the firm revealed some pretty upbeat targets during its latest Investor Day meeting.

Could Caterpillar really be in for a renaissance of growth over the next four years? Perhaps. A sales growth rate of around 6% seems easily doable, especially as buyers better appreciate its digital technologies.

That said, the business of construction, mining, and all the sort can be quite cyclical. And with that, investors had better have a tolerance for pain should the environment shift drastically. If a recession is encountered at some point down the road, the rosy sales guidance may be too high a bar that’s been set. Either way, I’m cautiously optimistic about the name while it’s trading for more than 23 times forward price-to-earnings (P/E). I could be wrong, but I think much of the optimism and strength might already be priced in here.

Goldman Sachs
Goldman Sachs (NYSE:GS) is up over 36% year to date, but more impressively, it’s up more than 142% in the last two years. The iconic investment bank really is firing on all cylinders, thanks to tons of dealmaking momentum, which is expected to carry into the new year, as well as continued resilience in the economy. If M&A looks to kick things up a few notches, the good days for Goldman Sachs might be about to get even better. In any case, the stock looks way too cheap at less than 15 times forward P/E, with a nice and growing 2.0%-yielding dividend.

While I’m no fan of chasing rallies, it’s hard to make a case against Goldman Sachs when it’s going for so cheap, with such macro tailwinds at its back. In the new year, I would not be surprised if shares top the S&P 500 once again. It’s a winner that has all the tools to continue winning big.
2025-11-11 16:36 5mo ago
2025-11-11 11:35 5mo ago
The U.S. government may open but that won't stop gold's rally - analysts stocknewsapi
AAAU BAR DBP DGL GLD GLDM IAU OUNZ SGOL UGL
Kitco News

The Leading News Source in Precious Metals

Kitco NEWS has a diverse team of journalists reporting on the economy, stock markets, commodities, cryptocurrencies, mining and metals with accuracy and objectivity. Our goal is to help people make informed market decisions through in-depth reporting, daily market roundups, interviews with prominent industry figures, comprehensive coverage (often exclusive) of important industry events and analyses of market-affecting developments.
2025-11-11 16:36 5mo ago
2025-11-11 11:35 5mo ago
DHI Group Q3 Earnings Beat Estimates, Revenues Rise Y/Y stocknewsapi
DHX
Key Takeaways DHI Group posted Q3 earnings of 9 cents per share, beating estimates by 50%.Revenues reached $32.1 million, down 9% year over year but above the consensus mark.Adjusted EBITDA rose 19% to $10.3 million, with margin expanding 800 basis points to 32%.
DHI Group (DHX - Free Report) reported third-quarter 2025 non-GAAP earnings of 9 cents per share, which beat the Zacks Consensus Estimate by 50%. DHX’s earnings improved 80% on a year-over-year basis.

DHI Group’s earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 154.3%.

DHX posted revenues of $32.1 million in the third quarter of 2025, surpassing the Zacks Consensus Estimate by 3.6%. DHX’s revenues declined 9% on a year-over-year basis.

DHX’s better-than-expected results helped its shares to rise 18.3% in the after-market hours on Nov. 10.

DHX Q3 in DetailDHX’s ClearanceJobs segment generated revenues of $13.9 million (43.3% of total revenues) in the third quarter of 2025, up 1% year over year. This segment was mainly driven by sustained demand for security-cleared technology professionals and improved customer retention capabilities due to the acquisition of AgileATS.

The Dice segment contributed $18.2 million (56.7% of total revenues), reflecting a 15% year-over-year decline. Although Dice’s revenues contracted in this quarter, its profitability improved significantly following restructuring efforts and the transition to a modern, self-service recruiting platform.

DHX’s adjusted EBITDA increased 19% year over year to $10.3 million and adjusted EBITDA margin increased 800 basis points to 32% in the third quarter of 2025.

Balance Sheet and Cash FlowsDHX posted a cash reserve of $2.3 million in the quarter ended Sept. 30 compared with $2.8 million posted in the previous quarter. The company’s total debt was $30 million in the third quarter of 2025.

DHX posted a free cash flow of $3.2 million, and its operating cash flows were $4.8 million in the third quarter of 2025.

DHX GuidanceFor the full-year 2025, DHI Group reaffirmed its revenue guidance of $126-$128 million. The Zacks Consensus Estimate for 2025 revenues is pegged at $126 million, indicating a year-over-year decline of 11.2%.

DHX’s fourth-quarter 2025 revenues are expected to be between $29.5 million and $31.5 million. The Zacks Consensus Estimate for fourth-quarter revenues is pegged at $30.7 million, indicating a year-over-year decline of 11.5%.

DHX raised its adjusted EBITDA margin guidance to 27% for 2025.

DHX’s Zacks Rank & Stocks to ConsiderCurrently, DHX carries a Zacks Rank #4 (Sell).

Some better-ranked stocks in the broader Computer and Technology sector are Dell Technologies (DELL - Free Report) , Nutanix (NTNX - Free Report) and Flux Power (FLUX - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Dell Technologies shares have appreciated 23.9% year to date. DELL is set to report the third quarter of fiscal 2026 results on Nov. 25.

Nutanix shares have gained 18.3% year to date. NTNX is set to report its first-quarter fiscal 2026 results on Nov. 25.

Flux Power shares have rallied 50% year to date. FLUX is set to report its first-quarter fiscal 2026 results on Nov. 13.
2025-11-11 15:36 5mo ago
2025-11-11 10:31 5mo ago
Steven Madden (SHOO) Reports Q3 Earnings: What Key Metrics Have to Say stocknewsapi
SHOO
Steven Madden (SHOO - Free Report) reported $667.88 million in revenue for the quarter ended September 2025, representing a year-over-year increase of 6.9%. EPS of $0.43 for the same period compares to $0.91 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $698.91 million, representing a surprise of -4.44%. The company delivered an EPS surprise of -2.27%, with the consensus EPS estimate being $0.44.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Steven Madden performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Revenue- International: $255.88 million compared to the $182.76 million average estimate based on two analysts. The reported number represents a change of +110.8% year over year.Revenue- Domestic: $411.99 million versus the two-analyst average estimate of $515.62 million. The reported number represents a year-over-year change of -18.1%.Revenue- Direct-to-Consumer: $221.5 million versus the three-analyst average estimate of $173.97 million. The reported number represents a year-over-year change of +76.5%.Revenue- Total Wholesale: $442.7 million versus $476.94 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -10.7% change.Total Revenue- Net Sales: $664.2 million versus the three-analyst average estimate of $650.91 million. The reported number represents a year-over-year change of +6.3%.Total Revenue- Wholesale Accessories/Apparel: $176.15 million compared to the $189.17 million average estimate based on three analysts. The reported number represents a change of -10.3% year over year.Total Revenue- Licensing fee income: $3.68 million compared to the $3.72 million average estimate based on three analysts. The reported number represents a change of +4.9% year over year.Total Revenue- Wholesale Footwear: $266.54 million versus $287.43 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -11% change.Income from operations- Wholesale: $55.72 million compared to the $66.36 million average estimate based on two analysts.Income from operations- Direct-to-Consumer: $-4.44 million compared to the $-7.44 million average estimate based on two analysts.Income from operations- Wholesale Accessories/Apparel: $15.6 million compared to the $21.07 million average estimate based on two analysts.Income from operations- Wholesale Footwear: $40.11 million compared to the $45.29 million average estimate based on two analysts.View all Key Company Metrics for Steven Madden here>>>

Shares of Steven Madden have returned +9.9% over the past month versus the Zacks S&P 500 composite's +4.4% change. The stock currently has a Zacks Rank #1 (Strong Buy), indicating that it could outperform the broader market in the near term.
2025-11-11 15:36 5mo ago
2025-11-11 10:31 5mo ago
Wall Street Bulls Look Optimistic About SentinelOne (S): Should You Buy? stocknewsapi
S
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about SentinelOne (S - Free Report) .

SentinelOne currently has an average brokerage recommendation (ABR) of 1.74, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 34 brokerage firms. An ABR of 1.74 approximates between Strong Buy and Buy.

Of the 34 recommendations that derive the current ABR, 21 are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 61.8% and 2.9% of all recommendations.

Brokerage Recommendation Trends for S

Check price target & stock forecast for SentinelOne here>>>

While the ABR calls for buying SentinelOne, it may not be wise to make an investment decision solely based on this information. Several studies have shown limited to no success of brokerage recommendations in guiding investors to pick stocks with the best price increase potential.

Do you wonder why? As a result of the vested interest of brokerage firms in a stock they cover, their analysts tend to rate it with a strong positive bias. According to our research, brokerage firms assign five "Strong Buy" recommendations for every "Strong Sell" recommendation.

This means that the interests of these institutions are not always aligned with those of retail investors, giving little insight into the direction of a stock's future price movement. It would therefore be best to use this information to validate your own analysis or a tool that has proven to be highly effective at predicting stock price movements.

With an impressive externally audited track record, our proprietary stock rating tool, the Zacks Rank, which classifies stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), is a reliable indicator of a stock's near-term price performance. So, validating the Zacks Rank with ABR could go a long way in making a profitable investment decision.

ABR Should Not Be Confused With Zacks RankIn spite of the fact that Zacks Rank and ABR both appear on a scale from 1 to 5, they are two completely different measures.

Broker recommendations are the sole basis for calculating the ABR, which is typically displayed in decimals (such as 1.28). The Zacks Rank, on the other hand, is a quantitative model designed to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.

It has been and continues to be the case that analysts employed by brokerage firms are overly optimistic with their recommendations. Because of their employers' vested interests, these analysts issue more favorable ratings than their research would support, misguiding investors far more often than helping them.

In contrast, the Zacks Rank is driven by earnings estimate revisions. And near-term stock price movements are strongly correlated with trends in earnings estimate revisions, according to empirical research.

In addition, the different Zacks Rank grades are applied proportionately to all stocks for which brokerage analysts provide current-year earnings estimates. In other words, this tool always maintains a balance among its five ranks.

Another key difference between the ABR and Zacks Rank is freshness. The ABR is not necessarily up-to-date when you look at it. But, since brokerage analysts keep revising their earnings estimates to account for a company's changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in indicating future price movements.

Is S Worth Investing In?In terms of earnings estimate revisions for SentinelOne, the Zacks Consensus Estimate for the current year has remained unchanged over the past month at $0.19.

Analysts' steady views regarding the company's earnings prospects, as indicated by an unchanged consensus estimate, could be a legitimate reason for the stock to perform in line with the broader market in the near term.

The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for SentinelOne. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

It may therefore be prudent to be a little cautious with the Buy-equivalent ABR for SentinelOne.
2025-11-11 15:36 5mo ago
2025-11-11 10:31 5mo ago
Axcelis Technologies (ACLS) Recently Broke Out Above the 50-Day Moving Average stocknewsapi
ACLS
From a technical perspective, Axcelis Technologies (ACLS - Free Report) is looking like an interesting pick, as it just reached a key level of support. ACLS recently overtook the 50-day moving average, and this suggests a short-term bullish trend.

The 50-day simple moving average is one of three major moving averages used by traders and analysts to determine support or resistance levels for a wide range of securities. But the 50-day is considered to be more important because it's the first marker of an up or down trend.

ACLS could be on the verge of another rally after moving 7.4% higher over the last four weeks. Plus, the company is currently a Zacks Rank #3 (Hold) stock.

The bullish case solidifies once investors consider ACLS's positive earnings estimate revisions. No estimate has gone lower in the past two months for the current fiscal year, compared to 4 higher, while the consensus estimate has increased too.

Given this move in earnings estimate revisions and the positive technical factor, investors may want to keep their eye on ACLS for more gains in the near future.
2025-11-11 15:36 5mo ago
2025-11-11 10:31 5mo ago
Wall Street Analysts Think AZZ (AZZ) Is a Good Investment: Is It? stocknewsapi
AZZ
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though?

Let's take a look at what these Wall Street heavyweights have to say about AZZ (AZZ - Free Report) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.

AZZ currently has an average brokerage recommendation (ABR) of 1.60, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 10 brokerage firms. An ABR of 1.60 approximates between Strong Buy and Buy.

Of the 10 recommendations that derive the current ABR, seven are Strong Buy, representing 70% of all recommendations.

Brokerage Recommendation Trends for AZZ

Check price target & stock forecast for AZZ here>>>

While the ABR calls for buying AZZ, it may not be wise to make an investment decision solely based on this information. Several studies have shown limited to no success of brokerage recommendations in guiding investors to pick stocks with the best price increase potential.

Are you wondering why? The vested interest of brokerage firms in a stock they cover often results in a strong positive bias of their analysts in rating it. Our research shows that for every "Strong Sell" recommendation, brokerage firms assign five "Strong Buy" recommendations.

This means that the interests of these institutions are not always aligned with those of retail investors, giving little insight into the direction of a stock's future price movement. It would therefore be best to use this information to validate your own analysis or a tool that has proven to be highly effective at predicting stock price movements.

With an impressive externally audited track record, our proprietary stock rating tool, the Zacks Rank, which classifies stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), is a reliable indicator of a stock's near-term price performance. So, validating the Zacks Rank with ABR could go a long way in making a profitable investment decision.

Zacks Rank Should Not Be Confused With ABRAlthough both Zacks Rank and ABR are displayed in a range of 1--5, they are different measures altogether.

The ABR is calculated solely based on brokerage recommendations and is typically displayed with decimals (example: 1.28). In contrast, the Zacks Rank is a quantitative model allowing investors to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.

It has been and continues to be the case that analysts employed by brokerage firms are overly optimistic with their recommendations. Because of their employers' vested interests, these analysts issue more favorable ratings than their research would support, misguiding investors far more often than helping them.

On the other hand, earnings estimate revisions are at the core of the Zacks Rank. And empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

In addition, the different Zacks Rank grades are applied proportionately to all stocks for which brokerage analysts provide current-year earnings estimates. In other words, this tool always maintains a balance among its five ranks.

Another key difference between the ABR and Zacks Rank is freshness. The ABR is not necessarily up-to-date when you look at it. But, since brokerage analysts keep revising their earnings estimates to account for a company's changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in indicating future price movements.

Is AZZ a Good Investment?In terms of earnings estimate revisions for AZZ, the Zacks Consensus Estimate for the current year has remained unchanged over the past month at $5.99.

Analysts' steady views regarding the company's earnings prospects, as indicated by an unchanged consensus estimate, could be a legitimate reason for the stock to perform in line with the broader market in the near term.

The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for AZZ. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

It may therefore be prudent to be a little cautious with the Buy-equivalent ABR for AZZ.
2025-11-11 15:36 5mo ago
2025-11-11 10:31 5mo ago
Compared to Estimates, Cantaloupe (CTLP) Q1 Earnings: A Look at Key Metrics stocknewsapi
CTLP
Cantaloupe (CTLP - Free Report) reported $80.85 million in revenue for the quarter ended September 2025, representing a year-over-year increase of 14.1%. EPS of $0.06 for the same period compares to $0.04 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $81.64 million, representing a surprise of -0.96%. The company delivered an EPS surprise of -25%, with the consensus EPS estimate being $0.08.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Cantaloupe performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Revenues- Subscription and transaction fees- Transaction fees: $48.06 million versus $50.79 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +10.2% change.Revenues- Equipment sales: $10.53 million versus $7.99 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +49.5% change.Revenues- Subscription and transaction fees: $70.33 million versus the two-analyst average estimate of $73.45 million. The reported number represents a year-over-year change of +10.2%.Revenues- Subscription and transaction fees- Subscription fees: $22.27 million versus $22.82 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +10.3% change.View all Key Company Metrics for Cantaloupe here>>>

Shares of Cantaloupe have returned -0.3% over the past month versus the Zacks S&P 500 composite's +4.4% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.
2025-11-11 15:36 5mo ago
2025-11-11 10:31 5mo ago
VALE (VALE) Is Considered a Good Investment by Brokers: Is That True? stocknewsapi
VALE
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though?

Let's take a look at what these Wall Street heavyweights have to say about VALE S.A. (VALE - Free Report) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.

VALE currently has an average brokerage recommendation (ABR) of 1.82, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 17 brokerage firms. An ABR of 1.82 approximates between Strong Buy and Buy.

Of the 17 recommendations that derive the current ABR, 10 are Strong Buy, representing 58.8% of all recommendations.

Brokerage Recommendation Trends for VALE

Check price target & stock forecast for VALE here>>>

The ABR suggests buying VALE, but making an investment decision solely on the basis of this information might not be a good idea. According to several studies, brokerage recommendations have little to no success guiding investors to choose stocks with the most potential for price appreciation.

Are you wondering why? The vested interest of brokerage firms in a stock they cover often results in a strong positive bias of their analysts in rating it. Our research shows that for every "Strong Sell" recommendation, brokerage firms assign five "Strong Buy" recommendations.

This means that the interests of these institutions are not always aligned with those of retail investors, giving little insight into the direction of a stock's future price movement. It would therefore be best to use this information to validate your own analysis or a tool that has proven to be highly effective at predicting stock price movements.

Zacks Rank, our proprietary stock rating tool with an impressive externally audited track record, categorizes stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), and is an effective indicator of a stock's price performance in the near future. Therefore, using the ABR to validate the Zacks Rank could be an efficient way of making a profitable investment decision.

Zacks Rank Should Not Be Confused With ABRAlthough both Zacks Rank and ABR are displayed in a range of 1--5, they are different measures altogether.

The ABR is calculated solely based on brokerage recommendations and is typically displayed with decimals (example: 1.28). In contrast, the Zacks Rank is a quantitative model allowing investors to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.

It has been and continues to be the case that analysts employed by brokerage firms are overly optimistic with their recommendations. Because of their employers' vested interests, these analysts issue more favorable ratings than their research would support, misguiding investors far more often than helping them.

In contrast, the Zacks Rank is driven by earnings estimate revisions. And near-term stock price movements are strongly correlated with trends in earnings estimate revisions, according to empirical research.

Furthermore, the different grades of the Zacks Rank are applied proportionately across all stocks for which brokerage analysts provide earnings estimates for the current year. In other words, at all times, this tool maintains a balance among the five ranks it assigns.

There is also a key difference between the ABR and Zacks Rank when it comes to freshness. When you look at the ABR, it may not be up-to-date. Nonetheless, since brokerage analysts constantly revise their earnings estimates to reflect changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in predicting future stock prices.

Is VALE a Good Investment?Looking at the earnings estimate revisions for VALE, the Zacks Consensus Estimate for the current year has increased 7.8% over the past month to $1.9.

Analysts' growing optimism over the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher, could be a legitimate reason for the stock to soar in the near term.

The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #1 (Strong Buy) for VALE. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

Therefore, the Buy-equivalent ABR for VALE may serve as a useful guide for investors.
2025-11-11 15:36 5mo ago
2025-11-11 10:31 5mo ago
Roivant Sciences Ltd. (ROIV) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript stocknewsapi
ROIV
Q2: 2025-11-10 Earnings SummaryEPS of -$0.28 beats by $0.03

 |

Revenue of

$1.57M

(-94.63% Y/Y)

misses by $4.73M

Roivant Sciences Ltd. (ROIV) Guggenheim Securities 2nd Annual Healthcare Innovation Conference November 11, 2025 8:00 AM EST

Company Participants

Richard Pulik - Chief Financial Officer

Conference Call Participants

Yatin Suneja - Guggenheim Securities, LLC, Research Division

Presentation

Yatin Suneja
Guggenheim Securities, LLC, Research Division

All right. Good morning, everyone. Welcome to Guggenheim Healthcare Innovation Conference. My name is Yatin Suneja, one of the biotech analysts here at Guggenheim. It is my pleasure to welcome Roivant Sciences here with me. From the company, we have the Chief Financial Officer, Richard Pulik. Richard, why don't you make some opening comments. You did the earnings call yesterday. There were some incremental updates. Why don't you just make some comments, and then we'll go into the Q&A.

Richard Pulik
Chief Financial Officer

Great. First of all, it's great to see everybody here, especially surprised to see people from the audience given some of the travel issues. So nice to see that there's actually some bodies here. Look, we've had incredible momentum since we read out the brepo dermatomyositis data and also the Graves' data. I think people are finally starting to see brepo as an asset that will be a large commercial asset that we plan to file next year and launch in '27. So I think there's been a lot of excitement around that from the KOL community, from patients. And I think the data speaks to itself that this is an incredibly devastating disease that impacts both skin and muscle, and we have data now with an oral solution that showed very strong efficacy across 10 endpoints that were statistically significant. It's probably in my 25-year career in health care, one of the cleanest trials I've seen.

And so I think that's brought a lot of excitement into the brepo story

Recommended For You
2025-11-11 15:36 5mo ago
2025-11-11 10:31 5mo ago
Here's What Key Metrics Tell Us About International Money Express (IMXI) Q3 Earnings stocknewsapi
IMXI
For the quarter ended September 2025, International Money Express (IMXI - Free Report) reported revenue of $154.92 million, down 9.9% over the same period last year. EPS came in at $0.38, compared to $0.61 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $163.35 million, representing a surprise of -5.16%. The company delivered an EPS surprise of -29.63%, with the consensus EPS estimate being $0.54.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how International Money Express performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Revenue- Other income: $4.85 million versus $2.35 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +42.9% change.Revenue- Foreign exchange gain, net: $22.28 million versus $24.4 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -7% change.Revenue- Wire transfer and money order fees, net: $127.8 million versus $136.65 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -11.6% change.View all Key Company Metrics for International Money Express here>>>

Shares of International Money Express have returned +3.1% over the past month versus the Zacks S&P 500 composite's +4.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
2025-11-11 15:36 5mo ago
2025-11-11 10:31 5mo ago
Unity Software Inc. (U) Crossed Above the 50-Day Moving Average: What That Means for Investors stocknewsapi
U
After reaching an important support level, Unity Software Inc. (U - Free Report) could be a good stock pick from a technical perspective. U surpassed resistance at the 50-day moving average, suggesting a short-term bullish trend.

The 50-day simple moving average is a widely used technical indicator that helps determine support or resistance levels for different types of securities. It's one of three major moving averages, but takes precedent because it's the first sign of an up or down trend.

Shares of U have been moving higher over the past four weeks, up 16.1%. Plus, the company is currently a Zacks Rank #3 (Hold) stock, suggesting that U could be poised for a continued surge.

Looking at U's earnings estimate revisions, investors will be even more convinced of the bullish uptrend. There have been 1 higher compared to none lower for the current fiscal year, and the consensus estimate has moved up as well.

Investors may want to watch U for more gains in the near future given the company's key technical level and positive earnings estimate revisions.
2025-11-11 15:36 5mo ago
2025-11-11 10:31 5mo ago
Brokers Suggest Investing in Boston Scientific (BSX): Read This Before Placing a Bet stocknewsapi
BSX
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Let's take a look at what these Wall Street heavyweights have to say about Boston Scientific (BSX - Free Report) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.

Boston Scientific currently has an average brokerage recommendation (ABR) of 1.22, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 32 brokerage firms. An ABR of 1.22 approximates between Strong Buy and Buy.

Of the 32 recommendations that derive the current ABR, 27 are Strong Buy and three are Buy. Strong Buy and Buy respectively account for 84.4% and 9.4% of all recommendations.

Brokerage Recommendation Trends for BSX

Check price target & stock forecast for Boston Scientific here>>>

The ABR suggests buying Boston Scientific, but making an investment decision solely on the basis of this information might not be a good idea. According to several studies, brokerage recommendations have little to no success guiding investors to choose stocks with the most potential for price appreciation.

Do you wonder why? As a result of the vested interest of brokerage firms in a stock they cover, their analysts tend to rate it with a strong positive bias. According to our research, brokerage firms assign five "Strong Buy" recommendations for every "Strong Sell" recommendation.

In other words, their interests aren't always aligned with retail investors, rarely indicating where the price of a stock could actually be heading. Therefore, the best use of this information could be validating your own research or an indicator that has proven to be highly successful in predicting a stock's price movement.

Zacks Rank, our proprietary stock rating tool with an impressive externally audited track record, categorizes stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), and is an effective indicator of a stock's price performance in the near future. Therefore, using the ABR to validate the Zacks Rank could be an efficient way of making a profitable investment decision.

ABR Should Not Be Confused With Zacks RankIn spite of the fact that Zacks Rank and ABR both appear on a scale from 1 to 5, they are two completely different measures.

Broker recommendations are the sole basis for calculating the ABR, which is typically displayed in decimals (such as 1.28). The Zacks Rank, on the other hand, is a quantitative model designed to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.

It has been and continues to be the case that analysts employed by brokerage firms are overly optimistic with their recommendations. Because of their employers' vested interests, these analysts issue more favorable ratings than their research would support, misguiding investors far more often than helping them.

In contrast, the Zacks Rank is driven by earnings estimate revisions. And near-term stock price movements are strongly correlated with trends in earnings estimate revisions, according to empirical research.

In addition, the different Zacks Rank grades are applied proportionately to all stocks for which brokerage analysts provide current-year earnings estimates. In other words, this tool always maintains a balance among its five ranks.

Another key difference between the ABR and Zacks Rank is freshness. The ABR is not necessarily up-to-date when you look at it. But, since brokerage analysts keep revising their earnings estimates to account for a company's changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in indicating future price movements.

Should You Invest in BSX?In terms of earnings estimate revisions for Boston Scientific, the Zacks Consensus Estimate for the current year has increased 2% over the past month to $3.03.

Analysts' growing optimism over the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher, could be a legitimate reason for the stock to soar in the near term.

The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #2 (Buy) for Boston Scientific. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

Therefore, the Buy-equivalent ABR for Boston Scientific may serve as a useful guide for investors.
2025-11-11 15:36 5mo ago
2025-11-11 10:31 5mo ago
Interpublic (IPG) Reports Q3 Earnings: What Key Metrics Have to Say stocknewsapi
IPG
For the quarter ended September 2025, Interpublic Group (IPG - Free Report) reported revenue of $2.14 billion, down 4.8% over the same period last year. EPS came in at $0.73, compared to $0.70 in the year-ago quarter.

The reported revenue represents a surprise of -2.34% over the Zacks Consensus Estimate of $2.19 billion. With the consensus EPS estimate being $0.71, the EPS surprise was +2.82%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Interpublic performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Revenue before billable expenses- International: $736.3 million versus the three-analyst average estimate of $770.9 million. The reported number represents a year-over-year change of -5%.Revenue before billable expenses- Domestic (United States): $1.4 billion versus the three-analyst average estimate of $1.42 billion. The reported number represents a year-over-year change of -4.7%.Revenue before billable expenses- International- Latin America: $88 million versus the two-analyst average estimate of $106.1 million. The reported number represents a year-over-year change of -21.4%.Revenue before billable expenses- International- Other: $142.1 million versus $136.93 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +5.4% change.Revenue before billable expenses- International- Continental Europe: $180 million compared to the $185.68 million average estimate based on two analysts. The reported number represents a change of +1.4% year over year.Revenue before billable expenses- International- United Kingdom: $181.4 million versus the two-analyst average estimate of $187.13 million. The reported number represents a year-over-year change of -6.4%.Revenue before billable expenses- International- Asia Pacific: $144.8 million compared to the $150.95 million average estimate based on two analysts. The reported number represents a change of -7.7% year over year.View all Key Company Metrics for Interpublic here>>>

Shares of Interpublic have returned -4.3% over the past month versus the Zacks S&P 500 composite's +4.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
2025-11-11 15:36 5mo ago
2025-11-11 10:31 5mo ago
Palantir Technologies Inc. (PLTR) Just Overtook the 50-Day Moving Average stocknewsapi
PLTR
Palantir Technologies Inc. (PLTR - Free Report) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, PLTR broke through the 50-day moving average, which suggests a short-term bullish trend.

The 50-day simple moving average is one of three major moving averages used by traders and analysts to determine support or resistance levels for a wide range of securities. But the 50-day is considered to be more important because it's the first marker of an up or down trend.

Over the past four weeks, PLTR has gained 9.3%. The company is currently ranked a Zacks Rank #2 (Buy), another strong indication the stock could move even higher.

Looking at PLTR's earnings estimate revisions, investors will be even more convinced of the bullish uptrend. There have been 9 higher compared to none lower for the current fiscal year, and the consensus estimate has moved up as well.

With a winning combination of earnings estimate revisions and hitting a key technical level, investors should keep their eye on PLTR for more gains in the near future.
2025-11-11 15:36 5mo ago
2025-11-11 10:31 5mo ago
Is Synopsys (SNPS) a Buy as Wall Street Analysts Look Optimistic? stocknewsapi
SNPS
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though?

Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Synopsys (SNPS - Free Report) .

Synopsys currently has an average brokerage recommendation (ABR) of 1.82, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 22 brokerage firms. An ABR of 1.82 approximates between Strong Buy and Buy.

Of the 22 recommendations that derive the current ABR, 15 are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 68.2% and 4.6% of all recommendations.

Brokerage Recommendation Trends for SNPS

Check price target & stock forecast for Synopsys here>>>

While the ABR calls for buying Synopsys, it may not be wise to make an investment decision solely based on this information. Several studies have shown limited to no success of brokerage recommendations in guiding investors to pick stocks with the best price increase potential.

Do you wonder why? As a result of the vested interest of brokerage firms in a stock they cover, their analysts tend to rate it with a strong positive bias. According to our research, brokerage firms assign five "Strong Buy" recommendations for every "Strong Sell" recommendation.

This means that the interests of these institutions are not always aligned with those of retail investors, giving little insight into the direction of a stock's future price movement. It would therefore be best to use this information to validate your own analysis or a tool that has proven to be highly effective at predicting stock price movements.

Zacks Rank, our proprietary stock rating tool with an impressive externally audited track record, categorizes stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), and is an effective indicator of a stock's price performance in the near future. Therefore, using the ABR to validate the Zacks Rank could be an efficient way of making a profitable investment decision.

ABR Should Not Be Confused With Zacks RankIn spite of the fact that Zacks Rank and ABR both appear on a scale from 1 to 5, they are two completely different measures.

The ABR is calculated solely based on brokerage recommendations and is typically displayed with decimals (example: 1.28). In contrast, the Zacks Rank is a quantitative model allowing investors to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.

It has been and continues to be the case that analysts employed by brokerage firms are overly optimistic with their recommendations. Because of their employers' vested interests, these analysts issue more favorable ratings than their research would support, misguiding investors far more often than helping them.

In contrast, the Zacks Rank is driven by earnings estimate revisions. And near-term stock price movements are strongly correlated with trends in earnings estimate revisions, according to empirical research.

Furthermore, the different grades of the Zacks Rank are applied proportionately across all stocks for which brokerage analysts provide earnings estimates for the current year. In other words, at all times, this tool maintains a balance among the five ranks it assigns.

There is also a key difference between the ABR and Zacks Rank when it comes to freshness. When you look at the ABR, it may not be up-to-date. Nonetheless, since brokerage analysts constantly revise their earnings estimates to reflect changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in predicting future stock prices.

Is SNPS Worth Investing In?Looking at the earnings estimate revisions for Synopsys, the Zacks Consensus Estimate for the current year has remained unchanged over the past month at $12.83.

Analysts' steady views regarding the company's earnings prospects, as indicated by an unchanged consensus estimate, could be a legitimate reason for the stock to perform in line with the broader market in the near term.

The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Synopsys. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

It may therefore be prudent to be a little cautious with the Buy-equivalent ABR for Synopsys.
2025-11-11 15:36 5mo ago
2025-11-11 10:31 5mo ago
Sea Limited (SE) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates stocknewsapi
SE
Sea Limited Sponsored ADR (SE - Free Report) reported $6.17 billion in revenue for the quarter ended September 2025, representing a year-over-year increase of 44.6%. EPS of $0.78 for the same period compares to $0.54 a year ago.

The reported revenue represents a surprise of +3.35% over the Zacks Consensus Estimate of $5.97 billion. With the consensus EPS estimate being $1.03, the EPS surprise was -24.27%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Sea Limited performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

E-commerce - Gross GMV: $32.2 million compared to the $31.93 million average estimate based on two analysts.Digital Entertainment - Quarterly active users: 671 versus the two-analyst average estimate of 682.E-commerce - Gross Orders: 3.6 billion versus the two-analyst average estimate of 3.5 billion.Digital Entertainment - Bookings: $840.7 million versus the two-analyst average estimate of $762.96 million.Digital Entertainment - Quarterly paying users: 66 compared to the 64 average estimate based on two analysts.Revenue- Digital entertainment: $653.03 million compared to the $538.84 million average estimate based on two analysts.Revenue- Other Services: $46.8 million compared to the $43.34 million average estimate based on two analysts. The reported number represents a change of +50.4% year over year.Revenue- Digital Financial Services: $989.86 million compared to the $969.74 million average estimate based on two analysts. The reported number represents a change of +60.8% year over year.Revenue- E-Commerce: $3.78 billion versus the two-analyst average estimate of $4.2 billion. The reported number represents a year-over-year change of +18.7%.Adjusted EBITDA- Digital Entertainment: $465.94 million compared to the $435.79 million average estimate based on two analysts.Adjusted EBITDA- E-commerce: $186.06 million compared to the $207.34 million average estimate based on two analysts.Adjusted EBITDA- Unallocated expenses: $-10.94 million versus the two-analyst average estimate of $-5.87 million.View all Key Company Metrics for Sea Limited here>>>

Shares of Sea Limited have returned -15.1% over the past month versus the Zacks S&P 500 composite's +4.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
2025-11-11 15:36 5mo ago
2025-11-11 10:31 5mo ago
Earnings Growth & Price Strength Make Alphabet (GOOGL) a Stock to Watch stocknewsapi
GOOG GOOGL
Here at Zacks, we offer our members many different opportunities to take full advantage of the stock market, as well as how to invest in ways that lead to long-term success.

The Zacks Premium service makes this easier. It features daily updates of the Zacks Rank and Zacks Industry Rank; full access to the Zacks #1 Rank List; Equity Research reports; and Premium stock screens like the Earnings ESP filter. All of these can help you quickly identify what stocks to buy, what to sell, and what are today's hottest industries.

Also included in Zacks Premium is the Focus List. This is a long-term portfolio of top stocks that have all the traits to beat the market.

Breaking Down the Zacks Focus ListIf you could, wouldn't you jump at the chance for access to a curated list of stocks to kickstart your investing journey?

Enter the Zacks Focus List. It's a portfolio made up of 50 stocks that are set to beat the market over the next 12 months; each company selected serves as a foundation for long-term investors looking to create an individual portfolio.

What makes the Focus List even more helpful is that each selection is accompanied by a full Zacks Analyst Report, which explains the reasoning behind every stock's selection and why we believe it's a good pick for the long-term.

The portfolio's past performance only solidifies why investors should consider it as a starting point. For 2020, the Focus List gained 13.85% on an annualized basis compared to the S&P 500's return of 9.38%. Cumulatively, the portfolio has returned 2,519.23% while the S&P returned 854.95%. Returns are for the period of February 1, 1996 to March 31, 2021.

Focus List MethodologyWhen stocks are picked for the Focus List, it reflects our enduring reliance on the power of earnings estimate revisions.

Earnings estimates are expectations of growth and profitability, and are determined by brokerage analysts. Together with company management, these analysts examine every aspect that may affect future earnings, like interest rates, the economy, and sector and industry optimism.

Earnings estimate revisions are very important, since investors also need to take into consideration what a company will earn in the future.

The stocks that receive positive changes to earnings estimates are more likely to receive even more upward changes in the future. Take this example: if an analyst raised their estimates last month, they'll probably do so again this month, and other analysts will follow.

Harnessing the power of earnings estimate revisions is where the Zacks Rank comes in. The Zacks Rank is a unique, proprietary stock-rating model that utilizes changes to a company's quarterly earnings expectations to help investors build a winning portfolio.

The Zacks Rank consists of four main pillars: Agreement, Magnitude, Upside, and Surprise. Each one is given a raw score, which is recalculated every night and compiled into the Rank. Then, stocks are classified into five groups, ranging from "Strong Buy" to "Strong Sell," using this data.

The Focus List is comprised of stocks hand-picked from a long list of #1 (Strong Buy) or #2 (Buy) ranked companies, meaning that each new addition boasts a bullish earnings consensus among analysts.

Since stock prices respond to revisions, it can be very profitable to buy stocks with rising earnings estimates. By buying Focus List stocks, then, you're likely getting into companies whose future earnings estimates will be raised, potentially leading to price momentum.

Focus List Spotlight: Alphabet (GOOGL - Free Report) Alphabet is one of the most innovative companies in the modern technological age. Over the last few years, the company has evolved from primarily a search-engine provider to cloud computing, ad-based video and music streaming, autonomous vehicles, healthcare and others. In the online search arena, Google has a monopoly with roughly 90% of the online search volume and market. Over the years, the company has witnessed increase in search queries, resulting from ongoing growth in user adoption and usage, primarily on mobile devices, continued growth in advertiser activity, and improvements in ad formats.

Since being added to the Focus List on May 19, 2025 at $166.19 per share, shares of GOOGL have increased 74.56% to $290.1. The stock is currently a #3 (Hold) on the Zacks Rank.

For fiscal 2025, 16 analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.47 to $10.46. GOOGL boasts an average earnings surprise of 18.7%.

Moreover, analysts are expecting GOOGL's earnings to grow 30.1% for the current fiscal year.

Reveal Winning StocksUnlock all of our powerful research, tools and analysis, including the Zacks #1 Rank List, Equity Research Reports, Zacks Earnings ESP Filter, Premium Screener and more, as part of Zacks Premium. You'll quickly identify which stocks to buy, hold and sell, and target today's hottest industries, to help improve the performance of your portfolio. Gain full access now >>
2025-11-11 15:36 5mo ago
2025-11-11 10:34 5mo ago
TMX Group and Coding for Veterans Open the Market to Observe Remembrance Day stocknewsapi
TMXXF
November 11, 2025 10:34 AM EST | Source: Toronto Stock Exchange
Toronto, Ontario--(Newsfile Corp. - November 11, 2025) - Jeff Musson, Executive Director of Coding for Veterans, and members of the Canadian Armed Forces (CAF), joined Dani Lipkin, Managing Director, Global Listings, Toronto Stock Exchange ("TSX"), to open the market in observance of Remembrance Day.

Cannot view this video? Visit:
https://www.youtube.com/watch?v=Al2GIMx7j14

Coding for Veterans is celebrating 1,000 enrolments in its programs, marking a significant milestone in its mission to support Canadian military veterans transitioning to civilian careers. Through specialized online training in software development, cybersecurity, and generative AI, the programs equip CAF members to build skills that lead to sustainable, rewarding careers in tech. Dedicated to honouring veteran service by offering pathways to high-demand tech roles, Coding for Veterans helps students go from deployment to employment.

"It's always a privilege to open the trading day at Toronto Stock Exchange," said Jeff Musson. "What better way to honour veteran service as they transition into civilian life than by providing them with the necessary training that leads to lasting and lucrative second careers in software development and cybersecurity."

MEDIA CONTACT:
Eiffie Cahill
Director of Events and Marketing
Coding for Veterans
[email protected]
519-319-1066

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/273990
2025-11-11 15:36 5mo ago
2025-11-11 10:34 5mo ago
Cogent Biosciences: Soaring On Blowout GIST Data - I Expect More Upside stocknewsapi
COGT
Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in COGT over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
2025-11-11 15:36 5mo ago
2025-11-11 10:35 5mo ago
ASML (ASML) Recently Broke Out Above the 20-Day Moving Average stocknewsapi
ASML
ASML (ASML - Free Report) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, ASML broke through the 20-day moving average, which suggests a short-term bullish trend.

A well-liked tool among traders, the 20-day simple moving average offers a look back at a stock's price over a 20-day period. This is very beneficial to short-term traders, as it smooths out short-term price trends and gives more trend reversal signals than longer-term moving averages.

Similar to other SMAs, if a stock's price moves above the 20-day, the trend is considered positive, while price falling below the moving average can signal a downward trend.

Shares of ASML have been moving higher over the past four weeks, up 5.5%. Plus, the company is currently a Zacks Rank #2 (Buy) stock, suggesting that ASML could be poised for a continued surge.

Looking at ASML's earnings estimate revisions, investors will be even more convinced of the bullish uptrend. There have been 4 revisions higher for the current fiscal year compared to none lower, and the consensus estimate has moved up as well.

Investors should think about putting ASML on their watchlist given the ultra-important technical indicator and positive move in earnings estimate revisions.
2025-11-11 15:36 5mo ago
2025-11-11 10:35 5mo ago
PagSeguro Digital Ltd. (PAGS) Crossed Above the 20-Day Moving Average: What That Means for Investors stocknewsapi
PAGS
After reaching an important support level, PagSeguro Digital Ltd. (PAGS - Free Report) could be a good stock pick from a technical perspective. PAGS surpassed resistance at the 20-day moving average, suggesting a short-term bullish trend.

The 20-day simple moving average is a popular investing tool. Traders like this SMA because it offers a look back at a stock's price over a shorter period and helps smooth out price fluctuations. The 20-day can also show more trend reversal signals than longer-term moving averages.

Like other SMAs, if a stock's price is moving above the 20-day, the trend is considered positive. When the price falls below the moving average, it can signal a downward trend.

PAGS has rallied 7.1% over the past four weeks, and the company is a Zacks Rank #3 (Hold) at the moment. This combination suggests PAGS could be on the verge of another move higher.

The bullish case only gets stronger once investors take into account PAGS's positive earnings estimate revisions. There have been 3 revisions higher for the current fiscal year compared to none lower, and the consensus estimate has moved up as well.

Given this move in earnings estimate revisions and the positive technical factor, investors may want to keep their eye on PAGS for more gains in the near future.
2025-11-11 15:36 5mo ago
2025-11-11 10:35 5mo ago
Down 30% in 4 Weeks, Here's Why You Should You Buy the Dip in Codexis (CDXS) stocknewsapi
CDXS
A downtrend has been apparent in Codexis (CDXS - Free Report) lately with too much selling pressure. The stock has declined 30% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround.

We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator that measures the speed and change of price movements.

RSI oscillates between zero and 100. Usually, a stock is considered oversold when its RSI reading falls below 30.

Technically, every stock oscillates between being overbought and oversold irrespective of the quality of their fundamentals. And the beauty of RSI is that it helps you quickly and easily check if a stock's price is reaching a point of reversal.

So, by this measure, if a stock has gotten too far below its fair value just because of unwarranted selling pressure, investors may start looking for entry opportunities in the stock for benefiting from the inevitable rebound.

However, like every investing tool, RSI has its limitations, and should not be used alone for making an investment decision.

Here's Why CDXS Could Experience a TurnaroundThe RSI reading of 25.05 for CDXS is an indication that the heavy selling could be in the process of exhausting itself, so the stock could bounce back in a quest for reaching the old equilibrium of supply and demand.

The RSI value is not the only factor that indicates a potential turnaround for the stock in the near term. On the fundamental side, there has been strong agreement among the sell-side analysts covering the stock in raising earnings estimates for the current year. Over the last 30 days, the consensus EPS estimate for CDXS has increased 0.5%. And an upward trend in earnings estimate revisions usually translates into price appreciation in the near term.

Moreover, CDXS currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises. This is a more conclusive indication of the stock's potential turnaround in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
2025-11-11 15:36 5mo ago
2025-11-11 10:35 5mo ago
Palantir Technologies Inc. (PLTR) Recently Broke Out Above the 20-Day Moving Average stocknewsapi
PLTR
After reaching an important support level, Palantir Technologies Inc. (PLTR - Free Report) could be a good stock pick from a technical perspective. PLTR surpassed resistance at the 20-day moving average, suggesting a short-term bullish trend.

The 20-day simple moving average is a popular investing tool. Traders like this SMA because it offers a look back at a stock's price over a shorter period and helps smooth out price fluctuations. The 20-day can also show more trend reversal signals than longer-term moving averages.

Like other SMAs, if a stock's price is moving above the 20-day, the trend is considered positive. When the price falls below the moving average, it can signal a downward trend.

PLTR has rallied 9.3% over the past four weeks, and the company is a Zacks Rank #2 (Buy) at the moment. This combination suggests PLTR could be on the verge of another move higher.

The bullish case solidifies once investors consider PLTR's positive earnings estimate revisions. No estimate has gone lower in the past two months for the current fiscal year, compared to 9 higher, while the consensus estimate has increased too.

Investors may want to watch PLTR for more gains in the near future given the company's key technical level and positive earnings estimate revisions.
2025-11-11 15:36 5mo ago
2025-11-11 10:35 5mo ago
Down 12.8% in 4 Weeks, Here's Why TriNet (TNET) Looks Ripe for a Turnaround stocknewsapi
TNET
A downtrend has been apparent in TriNet Group (TNET - Free Report) lately with too much selling pressure. The stock has declined 12.8% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround.

We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator that measures the speed and change of price movements.

RSI oscillates between zero and 100. Usually, a stock is considered oversold when its RSI reading falls below 30.

Technically, every stock oscillates between being overbought and oversold irrespective of the quality of their fundamentals. And the beauty of RSI is that it helps you quickly and easily check if a stock's price is reaching a point of reversal.

So, by this measure, if a stock has gotten too far below its fair value just because of unwarranted selling pressure, investors may start looking for entry opportunities in the stock for benefiting from the inevitable rebound.

However, like every investing tool, RSI has its limitations, and should not be used alone for making an investment decision.

Why a Trend Reversal is Due for TNETThe heavy selling of TNET shares appears to be in the process of exhausting itself, as indicated by its RSI reading of 29.75. So, the trend for the stock could reverse soon for reaching the old equilibrium of supply and demand.

This technical indicator is not the only factor that calls for a potential rebound for the stock. There is a fundamental indicator as well. A strong agreement among sell-side analysts covering TNET in raising earnings estimates for the current year has led to an increase in the consensus EPS estimate by 12.3% over the last 30 days. And an upward trend in earnings estimate revisions usually translates into price appreciation in the near term.

Moreover, TNET currently has a Zacks Rank #1 (Strong Buy), which means it is in the top 5% of more than 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises. This is a more conclusive indication of the stock's potential turnaround in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
2025-11-11 15:36 5mo ago
2025-11-11 10:35 5mo ago
Nvidia (NVDA) Crossed Above the 20-Day Moving Average: What That Means for Investors stocknewsapi
NVDA
Nvidia (NVDA - Free Report) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, NVDA broke through the 20-day moving average, which suggests a short-term bullish trend.

A well-liked tool among traders, the 20-day simple moving average offers a look back at a stock's price over a 20-day period. This is very beneficial to short-term traders, as it smooths out short-term price trends and gives more trend reversal signals than longer-term moving averages.

Like other SMAs, if a stock's price is moving above the 20-day, the trend is considered positive. When the price falls below the moving average, it can signal a downward trend.

Shares of NVDA have been moving higher over the past four weeks, up 5.7%. Plus, the company is currently a Zacks Rank #2 (Buy) stock, suggesting that NVDA could be poised for a continued surge.

Once investors consider NVDA's positive earnings estimate revisions, the bullish case only solidifies. No earnings estimate has been lowered in the past two months, compared to 3 raised estimates, for the current fiscal year, and the consensus estimate has increased as well.

Investors may want to watch NVDA for more gains in the near future given the company's key technical level and positive earnings estimate revisions.
2025-11-11 15:36 5mo ago
2025-11-11 10:35 5mo ago
Akebia Therapeutics (AKBA) Loses 39.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner stocknewsapi
AKBA
Akebia Therapeutics (AKBA - Free Report) has been on a downward spiral lately with significant selling pressure. After declining 39.9% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier.

We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator that measures the speed and change of price movements.

RSI oscillates between zero and 100. Usually, a stock is considered oversold when its RSI reading falls below 30.

Technically, every stock oscillates between being overbought and oversold irrespective of the quality of their fundamentals. And the beauty of RSI is that it helps you quickly and easily check if a stock's price is reaching a point of reversal.

So, by this measure, if a stock has gotten too far below its fair value just because of unwarranted selling pressure, investors may start looking for entry opportunities in the stock for benefiting from the inevitable rebound.

However, like every investing tool, RSI has its limitations, and should not be used alone for making an investment decision.

Here's Why AKBA Could Experience a TurnaroundThe RSI reading of 24.46 for AKBA is an indication that the heavy selling could be in the process of exhausting itself, so the stock could bounce back in a quest for reaching the old equilibrium of supply and demand.

This technical indicator is not the only factor that calls for a potential rebound for the stock. There is a fundamental indicator as well. A strong agreement among sell-side analysts covering AKBA in raising earnings estimates for the current year has led to an increase in the consensus EPS estimate by 100% over the last 30 days. And an upward trend in earnings estimate revisions usually translates into price appreciation in the near term.

Moreover, AKBA currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises. This is a more conclusive indication of the stock's potential turnaround in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
2025-11-11 15:36 5mo ago
2025-11-11 10:35 5mo ago
3 Oil Pipeline MLP Stocks to Watch Despite Industry Headwinds stocknewsapi
DK ET PAA
The midstream energy space is generally less vulnerable to fluctuations in oil and natural gas prices. Despite this, the outlook for the Zacks Oil and Gas - Pipeline MLP industry is gloomy now. With the conservative spending of exploration and production companies, demand for transportation and storage assets is not going to be lucrative.

Despite these developments, players like Delek US Holdings, Inc. (DK - Free Report) , Energy Transfer LP (ET - Free Report) and Plains All American Pipeline LP (PAA - Free Report) are well-positioned to sail through the prevailing uncertainties.

About the Industry
The Zacks Oil and Gas - Pipeline MLP industry comprises master limited partnerships (or MLPs) that primarily transport oil, natural gas, refined petroleum products and natural gas liquids (NGL) to consumers in North America. Apart from transporting the commodities, the partnerships have huge capacities to store oil, natural gas and petrochemical products.  The partnerships thus provide midstream services to producers and consumers of the commodities. The firms generate stable fee-based revenues from all these transportation and storage assets. The services provided by the MLPs entail the gathering and processing of commodities. The integrated midstream energy players also generate cashflows from ownership interests in fractionators and condensate distillation facilities.

What's Shaping the Future of Oil & Gas - Production & Pipelines Industry?
High Debt Load: The industry is inherently capital-intensive, as evident in the debt-to-capitalization ratio of 55.7%, where borrowing is a common practice to finance large infrastructure projects. However, elevated leverage can constrain financial flexibility, hindering midstream energy companies' capacity to invest in new developments, navigate economic downturns, or address unforeseen costs.

Shift to Renewables: Energy majors will increasingly face challenges in providing sustainable energy to the world while reducing greenhouse gas emissions. Thus, to address the issues of climate change, there will be a gradual shift from fossil fuels to renewable energy. This will lower the demand for the partnerships’ pipeline and storage networks for oil and natural gas.

Explorers’ Conservative Capital Spending: Oil and gas exploration and production companies are facing heightened pressure from investors to focus on stockholders’ returns rather than production. This is hindering the production growth of commodities, thereby denting the demand for pipeline and storage assets.

Zacks Industry Rank Indicates Weak Prospects
The Zacks Oil and Gas - Pipeline MLP industry is a six-stock group within the broader Zacks Oil - Energy sector. The industry currently carries a Zacks Industry Rank #190, which places it in the bottom 22% of more than 250 Zacks industries.

The group’s Zacks Industry Rank, which is basically the average of the Zacks Rank of all the member stocks, indicates dull near-term prospects. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

The industry’s position in the bottom 50% of the Zacks-ranked industries forms an unfavorable earnings outlook for the constituent stocks in aggregate. Before we present a few stocks that you may want to consider, let’s look at the industry’s recent stock market performance and its valuation picture.

Industry Underperforms Sector, S&P 500
The Zacks Oil and Gas - Pipeline MLP industry has underperformed the broader Zacks Oil - Energy sector and the Zacks S&P 500 Composite over the past year. The industry has declined 4.3% in the past year against the broader sector’s 7.6% gain and the S&P 500's 17.8% rise.

One-Year Price Performance

Industry's Current Valuation
Since midstream-focused oil and gas partnerships use fixed-rate debt for the majority of their borrowings, it makes sense to value them based on the EV/EBITDA (Enterprise Value/ Earnings before Interest, Tax, Depreciation and Amortization) ratio. This is because the valuation metric takes into account not just equity but also the level of debt.

On the basis of the trailing 12-month enterprise value-to-EBITDA (EV/EBITDA), the industry is currently trading at 10.49X, lower than the S&P 500’s 18.55X. It is, however, significantly above the sector’s trailing 12-month EV/EBITDA of 5.26X.

Over the past five years, the industry has traded as high as 12.57X and as low as 8.02X, with a median of 10.37X.

Trailing 12-Month Enterprise Value-to EBITDA (EV/EBITDA) Ratio

3 Oil & Gas Pipeline MLPs to Gain
Delek US Holdings is well poised to gain from its refining business since oil prices will likely continue to be softer, backed by increasing global oil inventories, per data from the U.S. Energy Information Administration. The bottom line of DK, carrying a Zacks Rank #3 (Hold), is likely to see growth of almost 40% in 2025.

Price and Consensus: DK

Energy Transfer has a stable business model with its huge pipeline network of natural gas, oil and refined petroleum products across 125,000 miles. The partnership has midstream assets in all the key basins in the United States, generating stable fee-based revenues.

Energy Transfer, with a Zacks Rank of 3, has offered a higher dividend yield than the composite stocks belonging to the industry over the past three consecutive years. For this year, the partnership is likely to see earnings growth of 7%.

Price and Consensus: ET

Plains All American Pipeline also enjoys stable fee-based revenues, banking on its oil and natural gas pipeline network and storage assets. Over the past seven days, the #3 Ranked stock has witnessed upward earnings estimate revisions for 2025. You can see the complete list of today’s Zacks #1 Rank stocks here.

Price and Consensus: PAA
2025-11-11 14:36 5mo ago
2025-11-11 09:21 5mo ago
Pembina Pipeline Q3 Earnings & Revenues Miss Estimates, Both Down Y/Y stocknewsapi
PBA
Key Takeaways PBA's Pipelines segment EBITDA rose 6.2%, driven by Peace and Alliance pipeline strength.Facilities segment EBITDA climbed to C$354 million, aided by Whitecap-related contributions.Marketing & New Ventures EBITDA dropped amid weaker NGL margins and higher input costs.
Pembina Pipeline Corporation (PBA - Free Report) reported third-quarter 2025 earnings per share of 31 cents, which missed the Zacks Consensus Estimate of 45 cents. The bottom line also decreased from the year-ago quarter’s level of 44 cents. This underperformance was primarily caused by weaker year-over-year results in the Marketing & New Ventures segment — including lower realized gains on derivatives and compressed NGL margins — as well as soft delivery in the Pipelines segment, with volumes of 2,750 mboe/d missing the consensus expectation of 2,768 mboe/d.

Quarterly revenues of $1.3 billion decreased about 3.8% year over year. The metric also missed the Zacks Consensus Estimate by 1.6%.

The Canada-based company’s operating cash flow decreased approximately 12.1% to C$810 million. Adjusted EBITDA increased 1.5% year over year to C$1 billion, driven by higher net revenues from the Peace Pipeline system and the Alliance Pipeline.

In the third quarter, the oil and gas storage and transportation company witnessed volumes of 3,959 mboe/d compared with 3,892 mboe/d reported in the prior-year quarter.

Pembina’s board of directors declared a quarterly cash dividend of 71 Canadian cents per share to its common shareholders of record as of Dec. 15. The payout will be paid on Dec. 31, 2025.

The company made meaningful progress across several growth initiatives. It secured new transportation commitments on the Peace Pipeline, renewing and adding roughly 50,000 barrels per day of volumes under agreements averaging about 10 years in term. Contract stability also improved on the Alliance Pipeline, with shippers using a one-time extension option and locking in a new 10-year toll on about 96% of available firm capacity. Pembina continued to advance more than C$1 billion in proposed pipeline expansions to support increasing production from the Montney, Duvernay and Deep Basin regions.

In addition, the company signed a 20-year agreement with PETRONAS covering 1.0 mtpa of its 1.5 mtpa capacity at the Cedar LNG facility. Pembina, together with its partner Kineticor, also moved the Greenlight Electricity Center closer to commercialization, with a final investment decision expected in the first half of 2026.

PBA’s Segmental InformationPipelines: Adjusted EBITDA of C$630 million increased about 6.2% from the year-ago quarter’s level.

This growth was mainly supported by stronger demand on seasonal contracts on the Alliance Pipeline, increased revenues on the Peace Pipeline system from higher tolls tied to contractual inflation adjustments, higher interruptible volumes on the Peace system and increased contracted volumes on the Nipisi Pipeline. However, the figure missed our projection of C$686.4 million.

Volumes in this segment also saw a 0.4% year-over-year increase to 2,750 mboe/d.

Facilities: Adjusted EBITDA of C$354 million increased from the year-ago quarter’s C$324 million, mainly driven by higher contribution from PGI related to transactions with Whitecap Resources Inc., increased capital recoveries due to a turnaround and higher volumes at the Duvernay Complex. The figure beat our projection of C$276.2 million. 

Volumes of 861 mboe/d increased about 6.3% year over year.

Marketing & New Ventures: Adjusted EBITDA of C$99 million decreased from the year-ago quarter’s C$159 million. This decrease was caused by lower net revenues, reflecting weaker NGL margins due to lower NGL prices, higher input natural gas costs at Aux Sable and lower realized gains on crude oil-based derivatives. However, the figure beat our projection of C$95.3 million.

This outcome was helped by a 1.2% increase in volumes from last year, reaching 348 mboe/d, showing steady activity in the segment.

PBA’s Capital Expenditure & Balance SheetPembina spent C$178 million as capital expenditure in the quarter under review compared with C$262 million a year ago.

As of Sept. 30, PBA had cash and cash equivalents worth C$149 million and C$12.6 billion in long-term debt. Debt-to-capitalization was 42.6%.

PBA’s 2025 GuidanceThis Zacks Rank #3 (Hold) company expects 2025 adjusted EBITDA in the range of C$4.25 billion to C$4.35 billion compared with the previous guidance of C$4.23 billion to C$4.43 billion.

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Important Earnings at a GlanceWhile we have discussed PBA’s third-quarter results in detail, let us take a look at three other key reports in this space.

Liberty Energy Inc. (LBRT - Free Report) , a leading pressure pumping and oilfield services firm headquartered in Denver, posted a third-quarter 2025 adjusted net loss of 6 cents per share, wider than the Zacks Consensus Estimate of a loss of 1 cent. Moreover, the bottom line decreased sharply from the year-ago quarter’s profit of 45 cents. The company's underperformance can be attributed to macroeconomic headwinds accompanied by a slowdown in the industry’s frac activity and market pricing pressure.

As of Sept. 30, Liberty Energy had approximately $13.4 million in cash and cash equivalents. The pressure pumper’s long-term debt of $253 million represented a debt-to-capitalization of 10.9%.

San Antonio-based Valero Energy Corporation (VLO - Free Report) , a leading independent refiner and marketer of transportation fuels and petrochemical products, reported third-quarter 2025 adjusted earnings of $3.66 per share, which beat the Zacks Consensus Estimate of $2.95. The bottom line improved from the year-ago quarter’s level of $1.16. Better-than-expected quarterly results can be primarily attributed to an increase in refining margins, higher ethanol margins and lower total cost of sales.

The company had cash and cash equivalents of $4.8 billion at the end of the third quarter. As of Sept. 30, 2025, it had a total debt of $8.4 billion and finance-lease obligations of $2.2 billion.

Houston-based Halliburton Company (HAL - Free Report) , one of the world’s largest oilfield services providers specializing in drilling and well completions, posted third-quarter 2025 adjusted net income per share of 58 cents, beating the Zacks Consensus Estimate of 50 cents. The outperformance primarily reflects successful cost reduction initiatives. However, the bottom line fell from the year-ago adjusted profit of 73 cents due to softer activity in North America.

As of Sept. 30, 2025, the company had approximately $2 billion in cash/cash equivalents and $7.2 billion in long-term debt, representing a debt-to-capitalization ratio of 41.1.
2025-11-11 14:36 5mo ago
2025-11-11 09:21 5mo ago
Gold Price Outlook – Gold Grinds Higher Early on Tuesday stocknewsapi
AAAU BAR DBP DGL GLD GLDM IAU OUNZ SGOL UGL
Gold Technical Analysis
The gold market has shown itself to be a little bit more bullish in the early hours here on Tuesday, although not as momentum driven as Monday. The question now is, can we continue to go higher? It does look like there is an area right around $4,150 that extends to the $4,200 level that I think will be defended. We’ll have to wait and see whether or not we can get above that area. I suspect, based on the price action so far during the day, it’s probably going to lead to a bit of a pullback.

The question at this point in time is whether we are forming the classic parabolic move to the upside, followed by a sell-off with distribution due to the massive amount of volume, a secondary attempt to break higher, and then failure. If we do, in fact, get that, it’s a good sign that maybe the bullish run for gold is over. On the other hand, once we get past the $4,200 level, then we start to talk about another leg higher.
2025-11-11 14:36 5mo ago
2025-11-11 09:21 5mo ago
Atai Beckley N.V. (ATAI) Discusses BPL-003 Phase IIb Open-Label Extension Study Results in Treatment Resistant Depression Transcript stocknewsapi
ATAI
Atai Beckley N.V. (ATAI) Discusses BPL-003 Phase IIb Open-Label Extension Study Results in Treatment Resistant Depression November 10, 2025 8:00 AM EST

Company Participants

Ashleigh Barreto
Srinivas Rao - Co-Founder, CEO & Executive Director
Kevin Craig - Chief Medical Officer
Robert Conley - Chief Research & Development Officer

Conference Call Participants

Lin Tsai - Jefferies LLC, Research Division
Ritu Baral - TD Cowen, Research Division
Pete Stavropoulos - Cantor Fitzgerald & Co., Research Division
Harry Gillis - Joh. Berenberg, Gossler & Co. KG, Research Division
Elemer Piros - Lucid Capital Markets, LLC, Research Division
Sumant Kulkarni - Canaccord Genuity Corp., Research Division
Patrick Trucchio - H.C. Wainwright & Co, LLC, Research Division
Ami Fadia - Needham & Company, LLC, Research Division

Presentation

Operator

Thank you for standing by. My name is Tina, and I will be your conference operator today. At this time, I would like to welcome everyone to the Atai Beckley BPL-003 phase IIb open-label extension study data conference call. [Operator Instructions]

It is now my pleasure to turn the call over to Ashleigh Barreto, Investor Relations at Atai Beckley. Please go ahead.

Ashleigh Barreto

Thank you, operator, and good morning, everyone. Before we begin, I would like to remind everyone that this call will contain forward-looking statements, which are subject to risks and uncertainties. Any statements regarding future events, results or expectations are forward-looking statements. Please note that these forward-looking statements reflect our opinions only as of the date of this call. We undertake no obligation to revise or update these forward-looking statements in light of new information or future events, except as required by law.

Information concerning factors that could cause actual results to differ materially from those contained in or implied by such forward-looking statements are discussed in greater detail in our recently filed 10-K available on our website or on sec.gov. I'd

Recommended For You
2025-11-11 14:36 5mo ago
2025-11-11 09:22 5mo ago
Microsoft: Why You'll Regret Selling Now (It's Not What You Think) stocknewsapi
MSFT
SummaryMicrosoft Corporation delivered strong Q1 FY' 26 results, with revenue and EPS surpassing estimates, yet shares fell ~7% post-earnings.MSFT's cloud and AI infrastructure demand remains robust, driving significant capital investment and positioning the company for accelerated growth in coming quarters.The strategic OpenAI partnership and major government AI adoption initiatives provide long-term growth catalysts and reinforce Azure's competitive edge.Despite recent stock weakness, MSFT's fundamentals and valuation support a Strong Buy rating, presenting an attractive entry point for long-term investors. tupungato/iStock Editorial via Getty Images

Microsoft Corporation (NASDAQ:MSFT) released its Q1 FY'26 earnings on October 29, 2025, and the numbers looked pretty solid. Revenue came in at $77.67 billion, outpacing estimates by 3.03%. Meanwhile, diluted EPS was $4.13 for

Analyst’s Disclosure:I/we have a beneficial long position in the shares of MSFT, GOOGL, AMZN either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You
2025-11-11 14:36 5mo ago
2025-11-11 09:23 5mo ago
aTyr Pharma, Inc. (ATYR) Failed Drug Trial Spurs Securities Lawsuit; Class Period Significantly Enlarged -- Hagens Berman stocknewsapi
ATYR
ATYR Investors with Losses Encouraged to Contact the Firm

, /PRNewswire/ -- A new class action complaint has been filed against aTyr Pharma, Inc. (NASDAQ: ATYR) and certain of its top executives, significantly enlarging the alleged class period covered by the ongoing securities litigation. The firm urges investors in aTyr who suffered significant losses to submit your losses now. The firm also encourages persons with knowledge who may be able to assist in the investigation to contact its attorneys.

The new class action, Kingv. aTyr Pharma Inc., filed in the U.S. District Court for the Southern District of California on behalf of investors who suffered substantial losses, now seeks to represent all persons and entities who acquired aTyr Pharma securities between November 7, 2024, and September 12, 2025, inclusive (the "Class Period"). The previous alleged Class Period began in January 2025, making this a critical expansion for investors who purchased shares in late 2024.

Prominent shareholders rights firm Hagens Berman has been investigating the alleged claims. Read more about the issue facing ATYR investors, The Stakes of Clinical Trials: Why Pharma Companies Must Be Accurate and How it Relates to the aTyr Investigation.

Expanded Class Period: Nov. 7, 2024 – Sep. 12, 2025
Lead Plaintiff Deadline: Dec. 8, 2025
Visit:www.hbsslaw.com/investor-fraud/atyr
Contact the Firm Now: [email protected]
                                          844-916-0895

aTyr Pharma, Inc. (AYTR) Securities Litigation:

The suits allege that aTyr and its top executives made false and misleading statements about the efficacy of its drug, Efzofitimod, leading investors to purchase stock at artificially inflated prices.

At the heart of the allegations is aTyr's Phase 3, randomized, double-blind, placebo-controlled study, known as EFZO-FIT, which evaluated intravenous Efzofitimod in patients with pulmonary sarcoidosis. The drug was intended to help patients reduce their dependency on steroids.

According to the complaint, throughout the Class Period, aTyr executives expressed overwhelmingly positive statements and confidence in the study's design, particularly its forced taper approach intended to gauge the drug's ability to allow patients to completely wean themselves off steroids.

However, the lawsuit claims that concurrently with these optimistic pronouncements, the company was allegedly concealing material adverse facts concerning Efzofitimod's capability to allow a patient to completely taper their steroid usage—a key measure of efficacy.  The lawsuit asserts that aTyr's statements crossed the line into securities law violations by allegedly misrepresenting the drug's true prospects.

The truth, as alleged in the complaint, came to light on Monday, September 15, 2025. Pre-market, aTyr hosted an investor call announcing that the EFZO-FIT study did not meet its primary endpoint: the change from baseline in mean daily oral corticosteroid (OSC) dose at week 48.

The disappointing topline results prompted a swift and brutal market reaction. aTyr's common stock, which had closed at $6.03 per share on the preceding Friday, September 12, cratered to close at just $1.02 per share on September 15—a catastrophic one-day decline of 83.2%.

In its post-announcement comments, the company stated that it would engage with the Food and Drug Administration (FDA) to determine a path forward, acknowledging the setback.

Hagens Berman's Investigation

Hagens Berman is investigating whether aTyr may have misled investors about its data and trial design while emphasizing Efzofitimod's multi-billion-dollar market opportunity.  "We're scrutinizing whether aTyr's previous representations about the drug's efficacy were materially misleading to investors," said Reed Kathrein, the Hagens Berman partner leading the firm's investigation.

If you invested in aTyr and have substantial losses, or have knowledge that may assist the firm's investigation, submit your losses now »

If you'd like more information and answers to frequently asked questions about the aTyr case and our investigation, read more »

Whistleblowers: Persons with non-public information regarding aTyr should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman
Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

SOURCE Hagens Berman Sobol Shapiro LLP
2025-11-11 14:36 5mo ago
2025-11-11 09:24 5mo ago
BigBear.ai: Q3 Beat Expectations, Yet The Real Test Is Still Ahead stocknewsapi
BBAI
Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
2025-11-11 14:36 5mo ago
2025-11-11 09:25 5mo ago
HealthStream Announces Share Repurchase Program stocknewsapi
HSTM
-

NASHVILLE, Tenn.--(BUSINESS WIRE)--HealthStream (Nasdaq: HSTM), a leading healthcare technology platform company for workforce solutions, today announced that its Board of Directors has approved a new share repurchase program for the Company’s common stock, under which the Company may repurchase up to $10 million of outstanding shares of common stock.

Pursuant to the authorization, repurchases may be made from time to time in the open market, including under a Rule 10b5-1 plan, through privately negotiated transactions, or otherwise. In addition, any repurchases under the authorization will be subject to prevailing market conditions, liquidity and cash flow considerations, applicable securities laws requirements (including under Rule 10b-18 and Rule 10b5-1 of the Securities Exchange Act of 1934, as applicable), and other factors. The share repurchase program will terminate on the earlier of February 26, 2026 or when the maximum dollar amount has been expended. The share repurchase program does not require the Company to acquire any amount of shares and may be suspended or discontinued at any time.

About HealthStream

HealthStream (Nasdaq: HSTM) is the healthcare industry’s largest ecosystem of platform-delivered workforce solutions that empowers healthcare professionals to do what they do best: deliver excellence in patient care. For more information, visit http://www.healthstream.com or call 615-301-3100.

This press release contains forward-looking statements that involve risks and uncertainties regarding HealthStream. This information has been included in reliance on the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such results or events predicted in these statements may differ materially from actual future events or results. These forward-looking statements are based on a variety of assumptions that may not be realized, and which are subject to significant risks and uncertainties, including that the anticipated financial and strategic benefits of the acquisition may not be realized, as well as risks and uncertainties referenced from time to time in the Company’s filings with the Securities and Exchange Commission.

More News From HealthStream

Back to Newsroom
2025-11-11 14:36 5mo ago
2025-11-11 09:25 5mo ago
Ondas Holdings to Report Q3 Earnings: How to Approach the Stock Now? stocknewsapi
ONDS
Key Takeaways Ondas Holdings will report Q3 2025 results on Nov. 13, with a projected loss of 5 cents per share.Revenues are estimated at $7.37 million, signaling a 398% year-over-year increase.Defense partnerships and OAS demand are expected to drive revenue and backlog expansion.
Ondas Holdings Inc. ((ONDS - Free Report) ) will release results for the third quarter of 2025 on Nov. 13.

ONDS’ earnings beat the Zacks Consensus Estimate in the last quarter while missing in the previous three quarters, with an average negative surprise of 17.95%.

Let us see how ONDS is expected to fare in terms of revenues and earnings this time.

The Zacks Consensus Estimate for the third-quarter 2025 bottom line stands at a loss of 5 cents, unchanged in the past 30 days. The Zacks Consensus Estimate for revenues is pegged at $7.37 million, indicating a 398% jump from the year-ago actual.

Image Source: Zacks Investment Research

Earnings Whispers for ONDSOur proven model does not predict an earnings beat for Ondas Holdings this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. This is not the case here.

ONDS currently has a Zacks Rank #2 and an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.

Factors Shaping ONDS Q3 ResultsContinued momentum in the Ondas Autonomous Systems (“OAS”) business division is likely to have buoyed the top-line performance. In the second quarter of 2025, ONDS’ revenues jumped more than 500% year over year to $6.3 million, driven almost entirely by OAS, which contributed $6.1 million compared with just $0.3 million a year earlier. The OAS had a backlog of $22 million at the end of the second quarter.

Ondas Holdings is expanding its footprint with new defense and homeland security customers across Europe, the Middle East and the United States. ONDS has been witnessing growing traction for both its Optimus System and Iron Drone Radar system and expects the Mistral partnership to boost U.S. government adoption of these two platforms.

The company’s recent partnership and investment in Rift Dynamics represents a key step toward localization efforts and capability expansion across European defense markets. Rift’s Wasp platform (a modular, low-cost, mass producible drone platform) complements Ondas Holdings' Optimus and Iron Drone Raider, boosting OAS’ defense portfolio. ONDS expects this partnership to help it gain share in the growing $1 billion-plus market for one-way attributable drones highlighted in the One Big Beautiful Bill and in ongoing “Replicator-2” initiatives.

In October, ONDS expanded the Rift partnership to include Nammo Raufoss AS, which is a provider of advanced munitions. Nammo has a solid manufacturing presence in the United States. As part of the deal, both companies will team up on a fully integrated Wasp drone with munition payloads and this will be sold entirely by Ondas Holdings' American Robotics in the United States.

In September, ONDS launched Ondas Capital. This new business division is solely focused on boosting the deployment of unmanned/autonomous systems to Allied defense and security markets.

Looking ahead, Ondas Holdings expects revenues for the full year to be at least $25 million, with at least $20 million coming from the OAS business unit. Management anticipates second-half bookings to surpass the $23 million attained in the first half, resulting in continued backlog expansion into 2026.

Nonetheless, heavy dependence on the OAS division for revenue growth in the increasingly crowded drone space is a concern.

If a single large customer delays, reduces or cancels, revenues would decline materially. Management acknowledged that revenues will fluctuate from quarter to quarter for OAS as it expands its client base. Moreover, revenues will vary as these customers enter fleet programs and recurring service agreements.While OAS dominates near-term revenues, Ondas Networks continues to build long-term value as a foundational enabler for next-generation rail communications.

Update on Inorganic ExpansionThe focus on M&A is expected to broaden capabilities and strengthen portfolio offerings.

It recently announced plans to acquire Sentry CS Ltd. Israel-based Sentry CS develops Cyber-over-RF and Protocol-Manipulation counter-UAS technology. Before that, it acquired a controlling interest in Insight Intelligent Sensors and in 4M Defense Ltd. Insight Intelligent Sensors specializes in the development of AI-driven electro-optical sensing systems. At the same time, 4M Defense is a smart demining company. 4M defense’s platform boasts advanced demining capabilities, like robotic systems with terrestrial and subsurface AI-powered intelligence tech.

In August, it entered into a definitive agreement to acquire a controlling 51% interest in Israel-based S.P.O Smart Precision Optics. This company is a manufacturer of advanced precision optical components and systems. It also announced the acquisition of Apeiro Motion, which develops advanced ground robotics, fiber optic communications systems and mission-critical automation technologies.

ONDS Stock SurgesONDS’ shares have skyrocketed 618.2% over the past six months, outperforming the Communication-Network software industry’s decline of 10.2%. The S&P 500 composite and the Zacks Computer and Technology sector have risen 17.7% and 30.3%, respectively, in the same time frame.

Image Source: Zacks Investment Research

ONDS’ Price Performance vs. PeersAeroVironment ((AVAV - Free Report) ), Draganfly ((DPRO - Free Report) ) and Unusual Machines ((UMAC - Free Report) ) stocks are up 99.7%, 343.5% and 115.4%, respectively, over the same time frame.

Draganfly is a Canada-based drone solutions and systems developer. The company’s drones include Commander 3XL, Heavy Lift Drone, Commander 2 and Draganfly Medical Response Drone. Unusual Machines is well-positioned within the evolving drone industry through its focus on manufacturing and selling (through B2B sales and a curated retail channel) small drones and essential components. The FPV segment is UMAC’s core operational area within the drone industry.

AeroVironment is a well-known name in drone technology. The company has been developing uncrewed aircraft and ground robot systems, loitering munitions systems and related services for the U.S. Department of Defense (including Army, Marine Corps, Special Operations Command, Air Force and Navy), other federal agencies and international allied governments. The acquisition of BlueHalo (May 2025) has added space technologies, counter-UAS, electronic warfare and cyber solutions to the portfolio.

Key Valuation Metric for ONDSONDS stock is trading at a substantial premium, with a forward 12-month price/sales of 29.85X compared with the industry’s 1.93X.

Image Source: Zacks Investment Research

In comparison, AVAV, DPRO and UMAC trade at multiples of 7.66X, 3.83X and 19.66X, respectively.

How to Approach ONDS Before Q3 Earnings ReleaseOndas Holdings’ operational momentum, underpinned by surging OAS revenues, an expanding $22 million backlog, and higher penetration across defense and homeland security markets, bodes well. With full-year revenue guidance of at least $25 million and second-half bookings expected to top the first half, ONDS remains a compelling high-growth play.
2025-11-11 14:36 5mo ago
2025-11-11 09:25 5mo ago
FCPT Boosts Portfolio With Strategic Veterinary Real Estate Purchase stocknewsapi
FCPT
Key Takeaways Four Corners Property Trust acquired five veterinary clinic properties for $13.8 million.The portfolio spans California, Florida, North Carolina and Texas under net leases averaging nine years.In Q3 2025, FCPT added 28 properties worth $82 million, diversifying across medical and retail sectors.
Four Corners Property Trust (FCPT - Free Report) recently announced the acquisition of a veterinary clinic portfolio comprising five properties for $13.8 million. The move underscores the company’s efforts to expand its portfolio as a strategy to remain resilient amid uncertain times.

The portfolio includes two National Veterinary Associates properties, two Banfield Pet Hospital properties and one Mission Pet Health property. Two of the five properties are located in strong retail corridors in California, and one each in Florida, North Carolina and Texas.

Priced at a 7.3% cap rate on rent as of the closing date of the transaction, the properties are corporate-operated under net leases with a weighted average remaining term of nine years.

FCPT: In a NutshellThis real estate investment trust (REIT), mainly engaged in the ownership and acquisition of high-quality, net-leased restaurant and retail properties, has a track record of acquisitions.

In the third quarter of 2025, FCPT acquired a total of 28 properties worth $82 million with a weighted average remaining lease term of 11.6 years. The acquired properties belonged to diverse industries, boosting the stability in revenue generation. 39% were medical, 36% auto service, 16% quick service restaurants and 9% casual dining restaurants by purchase price.

The above purchases fall in line with Four Corners’ strategy of structuring a portfolio that will withstand varied economic cycles. However, the company’s growth plans could encounter challenges due to its sizable $1.23 billion debt load, which may continue to keep borrowing costs high.

In the past three months, shares of this Zacks Rank #3 (Hold) company have declined 4.9% against the industry's growth of 3.4%.

Image Source: Zacks Investment Research

Stocks to ConsiderSome better-ranked stocks from the broader REIT sector are W.P. Carey (WPC - Free Report) and Terreno Realty (TRNO - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

The Zacks Consensus Estimate for WPC’s 2025 FFO per share has been moved northward over the past week to $4.92.

The consensus estimate for TRNO’s 2025 FFO per share has been revised upward marginally to $2.59 over the past month.

Note: Anything related to earnings presented in this write-up represents funds from operations (FFO), a widely used metric to gauge the performance of REITs.
2025-11-11 14:36 5mo ago
2025-11-11 09:26 5mo ago
SoftBank's $5.8 billion Nvidia stake sale stirs fresh AI bubble fears stocknewsapi
NVDA SFTBF SFTBY
SoftBank Group's $5.8 billion sale of its Nvidia stake jolted stock markets on Tuesday, stoking fears that the frenzy around artificial intelligence may have peaked, especially after recent warnings from Wall Street bank chiefs and a famed short seller.
2025-11-11 14:36 5mo ago
2025-11-11 09:27 5mo ago
MLTX SHAREHOLDER NOTICE: MoonLake Immunotherapeutics (MLTX) Faces Securities Class Action After Company Reported Disastrous Phase 3 Trial Data For Sole Drug Candidate -- Hagens Berman stocknewsapi
MLTX
, /PRNewswire/ -- A securities class action, styled Bridgewood v. MoonLake Immunotherapeutics, et al., No. 1:25-cv-08500 (S.D.N.Y), has been filed after MoonLake (NASDAQ: MLTX) announced disastrous Phase 3 trial results for its only product candidate (sonelokimab, or "SLK"), its highly anticipated treatment for patients with skin disease (hidradenitis suppurativa or "HS").

On this announcement, MoonLake investors saw the price of their shares crater $55.75, or about 90%, on September 29, 2025.

The development and severe market reaction has prompted national shareholders rights firm Hagens Berman to investigate claims that, prior to September 28, 2025, MoonLake misled investors about SLK's trial design and efficacy data.

The firm urges investors in MoonLake who suffered significant losses to submit your losses now. The firm also encourages persons with knowledge who may be able to assist in the investigation to contact its attorneys.

Class Period: Mar. 10, 2024 – Sep. 29, 2025
Lead Plaintiff Deadline: Dec. 15, 2025
Visit:www.hbsslaw.com/investor-fraud/mltx
Contact the Firm Now: [email protected]
                                        844-916-0895

MoonLake Immunotherapeutics (MLTX) Securities Class Action:

The litigation is focused on the propriety of MoonLake's statements about the trial design and data for SLK. The clinical stage biotechnology company is focused on skin inflammatory diseases driven by a cytokines known as IL-17A and IL-17F.

Central to SLK's commercial prospects was its ability to demonstrate efficacy in HS comparable or superior to a competitor's FDA-approved product ("BIMZELX"), which is used for the same HS indication and targets the same cytokines.

One difference between SLK and BIMZELX is that SLK's Nanobody structure is significantly smaller than BIMZELX's monoclonal antibody format.

Throughout the Class Period, MoonLake repeatedly touted SLK's structural advantages as translating into superior efficacy. The company has said that SLK could achieve benefits "a monoclonal antibody cannot do," that "the molecular advantages of our Nanobody translate into higher clinical responses for patients," and that Nanobodies "offer a more convenient and effective treatment."  

MoonLake also assured investors that "we really have a drug here that can become the gold standard and obviously that will facilitate any winning that we do with sonelokimab in HS."

The complaint alleges that these, and other, MoonLake statements were false and misleading statements and that the company withheld crucial information from investors. More specifically, the lawsuit claims that the company misled investors about the distinction between Nanobodies and monoclonal antibodies, including that (1) SLK and BIMZELX share the same molecular targets (IL-17A and IL-17F), (2) SLK's Nanobody structure would not confer a superior clinical benefit over the traditional monoclonal structure of BIMZELX, and (3) SLK's Nanobody structure purported increased tissue penetration would not translate to clinical efficacy.

Investors learned the truth on September 28, 2025 after MoonLake revealed that only one of its two SLK Phase 3 trials achieved statistical significance – and even those results demonstrated substantially lower efficacy than BIMZELX.  

On this news, the price of MoonLake shares cratered $55.75 (-90%) on September 29, 2025, with one analyst reportedly writing in a note to investors that the results "'arguably fall[] into the worst case outcome.'"

"We're focused on investors' losses and whether MoonLake may have intentionally misled investors about the SLK's purported advantages over BIMZELX while claiming that SLK could become a 'gold standard,'" said Reed Kathrein, the Hagens Berman partner leading the investigation.

If you invested in MoonLake and have substantial losses, or have knowledge that may assist the firm's investigation, submit your losses now »

If you'd like more information and answers to frequently asked questions about the MoonLake case and our investigation, read more »

Whistleblowers: Persons with non-public information regarding MoonLake should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman
Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

SOURCE Hagens Berman Sobol Shapiro LLP
2025-11-11 14:36 5mo ago
2025-11-11 09:28 5mo ago
JHX SHAREHOLDER NOTICE: James Hardie Industries (JHX) Lawsuit Alleges Securities Fraud Over Inventory Misstatements -- Hagens Berman stocknewsapi
JHX
, /PRNewswire/ -- A class-action lawsuit has been filed against James Hardie Industries plc (NYSE: JHX), the dominant producer of fiber cement building materials in the U.S., alleging the company committed securities fraud by misleading investors about inventory levels and customer demand in its crucial North American segment.

Hagens Berman is investigating the alleged claims and urges investors in James Hardie who suffered significant losses to contact the firm now.

Read more about the issue facing JHX investors, Alleged Inventory Deception: Investors Claim James Hardie Concealed Weak Demand.

Class Period: May 20, 2025 – Aug. 18, 2025
Lead Plaintiff Deadline: Dec. 23, 2025
Visit:www.hbsslaw.com/investor-fraud/jhx
Contact the Firm Now: [email protected]
                                       844-916-0895

The James Hardie Industries (JHX) Securities Class Action

The lawsuit, Laborers' District Council & Contractors' Pension Fund of Ohio v. James Hardie Industries PLC., et al., 25-cv-13018 (N.D. Ill.), filed on behalf of all investors who purchased or acquired James Hardie common stock—which converted from American Depositary Shares on July 1, 2025—between May 20, 2025, and August 18, 2025 (the "Class Period"), seeks damages for violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5.

The action centers on James Hardie's North America Fiber Cement segment, which the company states generates about 80% of its total earnings. The plaintiffs allege that despite the company starting to observe significant inventory destocking by its North American channel partners in April and early May 2025, management publicly denied the trend and assured investors of the segment's sustained strength.

Specifically, the complaint highlights statements made by company executives on or around May 20 and 21, 2025, which it claims falsely represented that customer demand remained robust and expressly denied that inventory destocking was occurring. The plaintiffs contend that these assurances concealed an underlying problem: sales were artificially inflated by "inventory loading by channel partners, with the hallmarks of fraudulent channel stuffing," rather than genuine, sustainable customer demand.

This alleged deception came to a head on August 19, 2025, when James Hardie belatedly disclosed a sharp decline in performance. The company reported that sales in the North America Fiber Cement division had dropped by 12%, attributing the decline to the very customer destocking it had previously denied, which management now admitted had been discovered "in April through May."

Company CEO and Executive Director Aaron Erter sought to frame the downturn as a "normalization of channel inventories," but cautioned that the impact was expected to affect sales for at least the next two quarters.

The market's reaction was severe and swift. Following the disclosure, James Hardie's common stock dropped by over 34%.

The plaintiffs argue that this precipitous decline—and the significant losses suffered by investors—was a direct result of the defendants' alleged wrongful acts and omissions during the Class Period. The lawsuit aims to recover damages on behalf of the Class Members who were financially injured by the sudden reversal of the company's reported financial health.

Hagens Berman's Investigation on Behalf of Investors

Hagens Berman is actively investigating the alleged claims.

"We want to know if James Hardie's sales were fueled by unsustainable sales practices and whether senior management was aware of the problem," said Reed Kathrein, the Hagens Berman partner leading the investigation.

If you invested in James Hardie and have substantial losses, or have knowledge that may assist the firm's investigation, submit your losses now »

If you'd like more information and answers to frequently asked questions about the James Hardie case and our investigation, read more »

Whistleblowers: Persons with non-public information regarding James Hardie should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman
Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

SOURCE Hagens Berman Sobol Shapiro LLP
2025-11-11 14:36 5mo ago
2025-11-11 09:29 5mo ago
Synopsys, Inc. (SNPS) Faces Securities Class Action Amid Q325 Results Revealing IP Business Problems -- Hagens Berman stocknewsapi
SNPS
SNPS Investors with Losses Encouraged to Contact the Firm

, /PRNewswire/ -- A securities fraud class action, styled Kim v. Synopsys, Inc., et al., No. 26-:cv-09410 (N.D.CA) has been filed and seeks to represent investors who purchased or otherwise acquired Synopsys, Inc. (NASDAQ: SNPS) securities between December 4, 2024 and September 9, 2025.

The lawsuit was filed after Synopsys announced disappointing Q3 2025 financial results, blaming underperformance in its IP business.

The development, which sent the price of Synopsys shares cratering $216.59 (-35%) on September 10, 2025, has prompted national shareholders rights firm Hagens Berman to investigate alleged claims that Synopsys misled investors about its customer risks and growth prospects.

The firm urges investors in Synopsys who suffered significant losses to submit your losses now. The firm also encourages persons with knowledge who may be able to assist in the investigation to contact its attorneys.

Class Period: December 4, 2024 – September 9, 2025
Lead Plaintiff Deadline: December 30, 2025
Visit:www.hbsslaw.com/investor-fraud/snps
Contact the Firm Now: [email protected]
                                       844-916-0895

Synopsys, Inc. (SNPS) Securities Class Action:

Synopsis delivers silicon design, IP, simulation and analysis solutions and design services to its customers. The company has two reportable segments – Design IP and Design Automation.

The litigation is focused on the propriety of Synopsys' assurances regarding the sustainability of revenue growth in its Design IP business. Design IP includes the company's interface, foundation, security, and embedded processor IP, IP subsystems, and IP implementation services.

In the past, Synopsis has touted its double-digit revenue growth in its Design IP business "as customers rely on Synopsis IP to minimize integration risk and speed time to market" and "our leading foundation and interface IP also expedites customer adoption of the latest protocols and leading-edge process nodes."

The lawsuit alleges that Synopsis made false and misleading statements while failing to disclose crucial information to investors about its business and prospects. More specifically, it claims that the company's increased focus on AI customers, which require additional customization, was deteriorating the economics of its Design IP business and, as a result, "certain road map and resource decisions" were unlikely to "yield their intended results."

Investors learned the truth on September 9, 2025, when Synopsys reported its Q3 2025 EPS of just $1.50, down 45% from the prior year quarter and down 33% sequentially. Synopsys mainly blamed the results on a nearly 8% decline in Design IP revenues as compared to the prior year quarter and acknowledged that "we need to pivot our IP resources and roadmap to the highest-growth opportunities."

This news drove the price of Synopsys shares down 36% the next day, its worst-ever single-day percentage decline since going public in 1992.

"We're investigating whether Synopsys may have misled investors about materialized risks to sustained Design IP revenue growth," said Reed Kathrein, the Hagens Berman partner leading the investigation.

If you invested in Synopsys and have substantial losses, or have knowledge that may assist the firm's investigation, submit your losses now »

If you'd like more information and answers to frequently asked questions about the Synopsys case and our investigation, read more »

Whistleblowers: Persons with non-public information regarding Synopsys should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman
Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

SOURCE Hagens Berman Sobol Shapiro LLP
2025-11-11 14:36 5mo ago
2025-11-11 09:29 5mo ago
Safety Insurance: A Juicy Dividend Hiding A Mediocre Business stocknewsapi
SAFT
Analyst’s Disclosure:I/we have a beneficial long position in the shares of CNA either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
2025-11-11 14:36 5mo ago
2025-11-11 09:30 5mo ago
Uniti Recognized Again by Military Friendly® Program for Its Focus on Hiring Veterans stocknewsapi
UNIT
LITTLE ROCK, Ark., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Uniti, a premier insurgent fiber provider dedicated to enabling mission-critical connectivity across the United States, has again been recognized by the Military Friendly® program for its initiatives to recruit, employ and retain military veterans.

“Uniti is honored that our abiding commitment to hire and retain military veterans continues to receive these prestigious accolades,” said Jennifer Ragsadale, executive vice president, chief administrative officer and chief people officer at Uniti. “Veterans and their spouses are vital to the success of our mission to deliver essential communications services to our customers.”

Uniti, segments of which were formerly Windstream, ranked second on the Military Friendly® Employer list and first on the Military Spouse Friendly lists for companies with annual revenue of $1 billion to $5 billion.

Institutions earning the Military Friendly® Employers designation were evaluated using both public data sources and responses from a proprietary survey. Over 2,900 organizations compete annually for the Military Friendly® designation.

Methodology, criteria, and weightings were determined by VIQTORY with input from the Military Friendly® Advisory Council of independent leaders in the military recruitment community. Final ratings were determined by combining an organization’s survey score with an assessment of the organization’s ability to meet thresholds for Recruitment, New Hire Retention, Employee Turnover, and Promotion and Advancement of veterans and military employees.

Windstream will be showcased in the 2026 Military Friendly® Employers Guide in the Winter issue of G.I. Jobs® magazine and on MilitaryFriendly.com.

To see available jobs at Uniti, please visit our careers site.

About Uniti:
Uniti (NASDAQ: UNIT) is a premier insurgent fiber provider dedicated to enabling mission-critical connectivity across the United States. We build, operate, and deliver fast and reliable communications services, empowering more than a million consumers and businesses in the digital economy. Our broad portfolio of services is offered through a suite of brands: Uniti Wholesale, Kinetic, Uniti Fiber, and Uniti Solutions. Visit us online at uniti.com. Engage with us on LinkedIn, X and Facebook.

Media Contact:

Scott Morris, 501-748-5342
[email protected]